Craniopharyngioma is a benign but locally aggressive epithelial tumor arising from Rathke's pouch remnants in the sellar/suprasellar region, commonly causing visual field defects, endocrine dysfunction, and hydrocephalus.

Craniopharyngioma

Craniopharyngioma is a benign (WHO Grade I), slow-growing, embryonic tumour arising from epithelial remnants of Rathke's pouch (the embryonic precursor of the anterior pituitary gland) ^[1]^[2]. The name breaks down as:

"Cranio-" = skull/cranium
"-pharyngi-" = pharynx (referring to Rathke's pouch, which is an ectodermal upgrowth from the embryonic oropharynx/stomodeum)
"-oma" = tumour

Despite being histologically benign, craniopharyngiomas behave in a clinically challenging manner because of their intimate anatomical relationship with the optic chiasm, hypothalamus, pituitary gland, third ventricle, and major cerebral vasculature — making complete surgical resection difficult and recurrence common ^[3].

Key Concept — 'Benign but Not Harmless'

In intracranial tumours, the concept of malignancy is different from extracranial tumours. A histologically benign tumour can display aggressive clinical behaviour — widely infiltrating, occupying functionally important areas, preventing complete removal. Craniopharyngioma is the poster child of this principle ^[3].

Feature	Detail
Incidence	0.5–2.5 per million per year (accounts for ~2–5% of all intracranial tumours)
Age distribution	Bimodal: childhood peak (5–15 years) and adult peak (45–65 years)
Paediatric importance	Most common suprasellar tumour in children; accounts for 5–10% of paediatric brain tumours
Sex	No significant sex predilection (M ≈ F)
Geography/Ethnicity	Higher incidence reported in Japan and parts of Africa; no specific Hong Kong preponderance but relevant in any paediatric sellar/suprasellar mass workup

"Craniopharyngiomas → children" — the classic pituitary region tumour of childhood, in contrast to pituitary adenomas → adults ^[1]^[2].

Key epidemiological points:

Symptoms appearing in childhood → 50% ^[2]
Symptoms appearing between 20–40 years → 25% ^[2]
The remaining ~25% present > 40 years

3. Anatomy and Functional Relationships

Understanding why craniopharyngiomas cause the problems they do requires understanding the anatomy of the sellar and suprasellar region.

During embryogenesis (weeks 4–8), the anterior pituitary (adenohypophysis) develops from Rathke's pouch, an ectodermal diverticulum that grows upward from the roof of the stomodeum (primitive oral cavity) toward the diencephalon. This pouch normally regresses, leaving only a vestigial cleft (Rathke's cleft) between the anterior and intermediate lobes of the pituitary. If nests of squamous epithelial cells from Rathke's pouch persist, they can give rise to:

Craniopharyngioma (neoplastic transformation)
Rathke's cleft cyst (non-neoplastic cystic remnant — an important differential)

Craniopharyngiomas can therefore arise anywhere along the path of Rathke's pouch migration — from the pharynx to the sella to the suprasellar space — though the vast majority are sellar/suprasellar.

Structure	Relationship	Clinical consequence if compressed/invaded
Optic chiasm	Directly superior to pituitary gland; craniopharyngiomas grow upward into this	Bitemporal hemianopia (classic); visual loss
Pituitary gland & stalk	Tumour compresses or infiltrates the gland/stalk	Hypopituitarism; disconnection hyperprolactinaemia; diabetes insipidus
Hypothalamus	Superior and posterior; tumour can adhere to hypothalamic floor	Hypothalamic dysfunction (obesity, temperature dysregulation, sleep disturbance, behavioural changes)
Third ventricle	Directly above; tumour can obstruct the foramen of Monro	Obstructive hydrocephalus
Cavernous sinuses	Lateral to sella; contain CN III, IV, V1, V2, VI and ICA	Cranial nerve palsies (rare in craniopharyngioma, more common in invasive pituitary adenomas)
Circle of Willis / ICA	Tumour can encase vessels	Stroke risk during surgery; rarely symptomatic preoperatively
Frontal lobes	Large tumours extend superiorly	Cognitive and personality changes

The pituitary stalk (infundibulum) carries:

Portal vessels — delivering hypothalamic releasing/inhibiting hormones to the anterior pituitary
Axons from supraoptic and paraventricular nuclei — transporting ADH (vasopressin) and oxytocin to the posterior pituitary

Stalk compression or damage therefore causes:

Diabetes insipidus — because ADH-carrying axons are interrupted → no ADH release → kidneys cannot concentrate urine → polyuria and polydipsia ^[2]
Disconnection (stalk-effect) hyperprolactinaemia — because dopamine (the prolactin-inhibiting factor) normally travels down the portal vessels to tonically suppress prolactin secretion. If the stalk is compressed, dopamine cannot reach the lactotrophs → prolactin rises (typically mild elevation, usually < 100–150 ng/mL, in contrast to prolactinomas which typically produce prolactin > 200 ng/mL if macroadenoma) ^[4]

High Yield — Stalk Effect vs Prolactinoma

Disconnection hyperprolactinaemia: prolactin usually mildly elevated (< 100–150 ng/mL) because dopamine inhibition is simply removed. In contrast, a prolactinoma (macroadenoma): prolactin is usually > 200 ng/mL (often > 10× ULN) because the tumour itself actively secretes prolactin ^[4]. This distinction is critical — you must not misdiagnose a craniopharyngioma as a prolactinoma!

4. Aetiology and Pathophysiology

Craniopharyngiomas are congenital in origin — they arise from embryonic remnants. The exact trigger for neoplastic transformation is not fully understood, but molecular pathology has revealed distinct driver mutations depending on the histological subtype:

Histological Subtype	Driver Mutation	Typical Age Group
Adamantinomatous	CTNNB1 (β-catenin) mutation → activates Wnt signalling pathway	Children and young adults (bimodal, but the paediatric peak)
Papillary	BRAF V600E mutation → activates MAPK/ERK signalling pathway	Adults (> 40 years, almost exclusively)

CTNNB1 mutation → nuclear accumulation of β-catenin → constitutive activation of Wnt pathway → cell proliferation and tumourigenesis. This is the same Wnt pathway involved in many developmental processes, hence its association with an embryonic-type tumour.
BRAF V600E mutation → constitutive activation of the RAS–RAF–MEK–ERK cascade → uncontrolled cell growth. This is the same mutation seen in melanoma, papillary thyroid cancer, and hairy cell leukaemia — and it is targetable by BRAF inhibitors (vemurafenib, dabrafenib) ± MEK inhibitors (trametinib), which represents a new therapeutic frontier (more on this in management).

These are essentially mutually exclusive — a craniopharyngioma has one or the other, never both. This distinction has important therapeutic implications in 2025–2026.

4.2 Pathology

Gross: typically cystic or mixed solid-cystic; cyst fluid is classically described as "machinery oil" — dark, viscous, cholesterol-rich fluid
Microscopy: resembles adamantinoma (ameloblastoma) of the jaw — wet keratin, calcification, palisading squamous epithelium, stellate reticulum
Calcification is very common (~50–90%) — this is the hallmark radiological feature ^[2]
Behaviour: tends to be adherent to surrounding structures (hypothalamus, optic apparatus), making complete resection challenging; higher recurrence rate

"Presence of calcifications → 50%" (lecture slide figure; note that most modern series report up to 70–90% in the adamantinomatous subtype) ^[2]

Gross: typically solid or mixed, less often purely cystic; less viscous cyst fluid
Microscopy: well-differentiated squamous papillae without wet keratin or calcification
Behaviour: usually does NOT calcify, tends to be better demarcated (less adherent to hypothalamus), lower recurrence rate, better surgical outcome
Almost exclusively in adults

Exam Tip — Calcification

A calcified suprasellar mass in a child = craniopharyngioma until proven otherwise. This is one of the most classic radiological associations in all of medicine ^[2]^[3].

The tumour itself is hormonally inert (it does not secrete pituitary hormones). All clinical effects are due to mass effect on surrounding structures:

5. Classification

Craniopharyngioma is classified under "Tumours of the Sellar Region":

WHO Grade 1 (histologically benign)
Two subtypes:
1. Adamantinomatous craniopharyngioma (CTNNB1-mutant)
2. Papillary craniopharyngioma (BRAF V600E-mutant)

Important for surgical planning:

Location	Description
Purely sellar (intrasellar)	Rare (~5%); mimics pituitary adenoma
Sellar + suprasellar	Most common (~75%)
Purely suprasellar	~20%; above the diaphragma sellae
Infrasellar (pharyngeal)	Extremely rare; extends into sphenoid sinus/nasopharynx
Third ventricular	Extension into or origin within 3rd ventricle

Feature	Adamantinomatous	Papillary
Age	Bimodal (children + adults)	Adults (> 40 y) almost exclusively
Mutation	CTNNB1 (β-catenin)	BRAF V600E
Calcification	Very common (50–90%)	Rare
Cyst content	"Machinery oil" (cholesterol-rich)	Less characteristic
Histology	Wet keratin, palisading epithelium, stellate reticulum, calcification	Well-differentiated squamous papillae
Adherence to brain	Often firmly adherent to hypothalamus	Better demarcated
Recurrence	Higher	Lower
Targeted therapy potential	Limited (Wnt pathway inhibitors in research)	BRAF ± MEK inhibitors (vemurafenib + trametinib)

6. Clinical Features

Four classical ways craniopharyngiomas present ^[2]:

Hypopituitarism → growth retardation in the child

Compression of pituitary stalk → diabetes insipidus

Chiasmal compression → bitemporal hemianopia (common)

Obstruction of the third ventricle → hydrocephalus

The presentation varies by age:

Children: growth failure, delayed puberty, visual loss, headache, raised ICP
Adults: visual disturbance, headaches, hormonal dysfunction (hypogonadism, hypothyroidism)

6.1 Symptoms (with Pathophysiological Basis)

Symptom	Mechanism
Bitemporal hemianopia	Tumour grows upward and compresses the optic chiasm from below. The crossing nasal retinal fibres (which carry temporal visual field information) are compressed first → loss of temporal fields bilaterally. This is the classic visual field defect ^[2]^[4]
Progressive visual loss / blurred vision	Continued compression of optic nerves or chiasm → optic atrophy
Unilateral visual loss	Preferential compression of one optic nerve (asymmetric growth)
Homonymous hemianopia	Rare — occurs if tumour extends posterolaterally to compress one optic tract ^[4]

Why temporal fields first? At the chiasm, the nasal retinal fibres (which see the temporal visual field) cross over. These crossing fibres are anatomically in the midline and therefore are compressed first by a midline suprasellar mass growing upward.

Symptom	Hormone Affected	Mechanism
Growth retardation / short stature (children)	GH deficiency	Direct compression of somatotrophs in the anterior pituitary or disruption of GHRH delivery via stalk compression; GH is the first axis to be lost in anterior pituitary failure ^[1]^[2]
Delayed or arrested puberty (children/adolescents)	FSH/LH (gonadotropin) deficiency	Compression of gonadotrophs or GnRH delivery disruption; FSH/LH axis is the second most vulnerable
Amenorrhoea (females) / Erectile dysfunction (males)	FSH/LH deficiency	Hypogonadotropic hypogonadism → ↓oestrogen/testosterone
Fatigue, weight gain, cold intolerance	TSH deficiency → secondary hypothyroidism	Compression of thyrotrophs or TRH delivery disruption
Fatigue, hypotension, hypoglycaemia, acute crisis	ACTH deficiency → secondary adrenal insufficiency	Compression of corticotrophs or CRH delivery disruption; ACTH deficiency is the most dangerous because it can cause adrenal crisis
Polyuria, polydipsia, nocturia	ADH deficiency → cranial diabetes insipidus	Compression or destruction of the pituitary stalk interrupts ADH transport from hypothalamic nuclei to the posterior pituitary ^[2]
Galactorrhoea ± amenorrhoea	Disconnection hyperprolactinaemia	Stalk compression → loss of dopaminergic inhibition → mild prolactin elevation

Order of Pituitary Hormone Loss in Compression

The classic teaching for the order of anterior pituitary hormone loss due to mass compression is: GH → FSH/LH → TSH → ACTH (mnemonic: "Go Look For The Adenoma"). GH-producing somatotrophs are most vulnerable because they make up ~50% of the anterior pituitary and are the first affected. However, in practice, any combination can occur ^[4].

In children specifically:

Growth failure is often the earliest and most common endocrine manifestation — the child falls off the growth curve over months to years. Unfortunately, this is often noticed late.
Diencephalic syndrome (in infants/young children): paradoxical emaciation (failure to thrive) despite adequate or increased caloric intake, hyperalertness, and euphoria. This is caused by anterior hypothalamic dysfunction disrupting energy balance regulation ^[1].

"Craniopharyngioma: arise in suprasellar region → VF defect, hypopituitarism, diencephalic syndrome" ^[1]

Symptom	Mechanism
Headache (generalised, dull, worse in the morning, worse with coughing/straining)	Stretching of the diaphragma sellae / dura by the expanding mass; if hydrocephalus develops, then raised ICP from ↑CSF volume ^[3]^[4]
Nausea and vomiting (especially projectile)	Raised ICP stimulates the area postrema (vomiting centre) in the medulla; also direct pressure on hypothalamic centres
Decreased consciousness / drowsiness	Raised ICP → ↓cerebral perfusion; compression of reticular activating system
Papilloedema (if chronic)	↑ICP → transmitted along subarachnoid space of optic nerve sheath → impaired axoplasmic transport → disc swelling ^[5]

S/S of ↑ICP: generalised, dull, constant headache (worse in morning), vomiting, ↓consciousness, papilloedema, Cushing's triad (late features), brain herniation ^[3]

Why worse in the morning? During sleep/recumbency, venous return from the brain is reduced (no gravity-assisted drainage), and CO₂ retention during sleep causes cerebral vasodilation → both increase ICP, which is already elevated.

Symptom	Mechanism
Hypothalamic obesity	Damage to ventromedial hypothalamus (satiety centre) → insatiable appetite and metabolic dysregulation; also ↓GH, ↓thyroid function contribute
Sleep disturbance (hypersomnia, disturbed sleep-wake cycle)	Damage to suprachiasmatic nucleus (circadian rhythm) and other sleep-regulatory hypothalamic nuclei
Temperature dysregulation	Damage to anterior hypothalamus (heat dissipation centre) or posterior hypothalamus (heat conservation centre)
Behavioural/personality changes	Disruption of hypothalamic-limbic connections
Memory impairment	Damage to mammillary bodies or fornix (part of Papez circuit)
Autonomic dysfunction	Hypothalamic centres regulate autonomic outflow

Hypothalamic morbidity is the most devastating long-term consequence of craniopharyngioma and its treatment. It is a major cause of reduced quality of life even after "successful" tumour removal.

Symptom	Mechanism
Cognitive decline / poor school performance (children)	Mass effect on frontal lobes, hypothalamus; hydrocephalus
Seizures	Rare; only if tumour extends to involve cortex (supratentorial)

6.2 Signs (with Pathophysiological Basis)

Sign	Mechanism
Bitemporal hemianopia on confrontation/perimetry	Optic chiasm compression — crossing nasal fibres
Reduced visual acuity	Optic nerve compression → axonal damage
Optic atrophy (pale disc on fundoscopy)	Chronic compression → Wallerian degeneration of optic nerve fibres
Papilloedema (swollen disc)	Raised ICP (if hydrocephalus); note that direct optic nerve compression causes optic atrophy, NOT papilloedema — you can have papilloedema in the contralateral eye and optic atrophy in the ipsilateral eye (Foster Kennedy syndrome, though this is more classically seen with olfactory groove meningiomas)
Relative afferent pupillary defect (RAPD)	Asymmetric optic nerve compression

Sign	Hormone Affected	Explanation
Short stature / growth failure (children)	GH deficiency	GH is essential for linear growth; GH-deficient children are proportionately short, often chubby (GH is lipolytic — its absence → fat accumulation)
Absent/delayed secondary sexual characteristics	FSH/LH deficiency	No pubertal development — Tanner stage I persistent, small testes in boys, absent breast development in girls
Dry, coarse skin; bradycardia; delayed relaxation of reflexes	TSH deficiency → hypothyroidism	Loss of thyroid hormone effects
Pallor, postural hypotension, ↓axillary/pubic hair	ACTH deficiency	↓Cortisol → circulatory collapse tendency; ↓androgens (adrenal) → hair loss. Note: unlike primary adrenal insufficiency, there is NO hyperpigmentation (because ACTH is LOW, not high)
Galactorrhoea (breast milk expression on examination)	Hyperprolactinaemia	Loss of dopamine inhibition
Signs of dehydration (if DI is severe)	ADH deficiency	Massive free water loss in urine

Sign	Mechanism
Papilloedema / CN VI palsy (false localizing sign)	Raised ICP — CN VI has the longest intracranial course and is stretched over the petrous apex with raised ICP → lateral rectus palsy → esotropia (eye turns inward)
Cognitive impairment, personality change	Frontal lobe / hypothalamic compression
Cushing's triad (hypertension + bradycardia + irregular respiration)	Late sign of critically raised ICP → brainstem herniation compressing medulla

Sign	Explanation
Obesity (often central)	Hypothalamic damage + GH/thyroid deficiency
Stunted growth with relative obesity	Classic paediatric presentation — short, overweight child with visual problems

7. Clinical Approach — Pattern Recognition

Think craniopharyngioma when you see:

Growth failure + visual field defects + headache ± diabetes insipidus
A calcified suprasellar mass on imaging

Think craniopharyngioma when you see:

Visual loss + hypopituitarism + suprasellar cystic mass ± calcification
Differentiate from pituitary macroadenoma (more common in adults) and Rathke's cleft cyst

Clinical Pearl — Time Course

Craniopharyngiomas are slow-growing. Symptoms often develop insidiously over months to years. Growth failure in a child may be the earliest sign but is often attributed to constitutional delay before the tumour is diagnosed. A high index of suspicion is needed.

Feature	Detail
Origin	Rathke's pouch remnants
WHO Grade	I (benign)
Subtypes	Adamantinomatous (CTNNB1); Papillary (BRAF V600E)
Age	Bimodal: 5–15 y and 45–65 y
Location	Sellar/suprasellar (most common)
Radiological hallmark	Calcified, cystic suprasellar mass
Four cardinal presentations	1. Hypopituitarism (GH deficiency → growth failure)
	2. DI (stalk compression)
	3. Bitemporal hemianopia (chiasm compression)
	4. Hydrocephalus (3rd ventricle obstruction)
Cyst fluid	"Machinery oil" (cholesterol-rich) — adamantinomatous
Behaviour	Benign histology but clinically aggressive due to location

High Yield Summary

Craniopharyngioma = benign (WHO Grade I) tumour from Rathke's pouch remnants, most common suprasellar tumour in children.
Two subtypes: Adamantinomatous (CTNNB1 mutation, children, calcified, "machinery oil" cyst, adherent) vs Papillary (BRAF V600E, adults, rarely calcified, better demarcated).
Calcified suprasellar mass in a child = craniopharyngioma until proven otherwise.
Four classical presentations: (1) Hypopituitarism → growth retardation; (2) Pituitary stalk compression → DI; (3) Chiasmal compression → bitemporal hemianopia; (4) Third ventricle obstruction → hydrocephalus.
Stalk compression causes both DI (ADH axon interruption) and disconnection hyperprolactinaemia (loss of dopamine inhibition; prolactin usually < 100–150 ng/mL — distinguish from prolactinoma).
Order of pituitary hormone loss: GH → FSH/LH → TSH → ACTH.
Hypothalamic morbidity (obesity, temperature dysregulation, sleep/behavioural disturbance) is the most devastating long-term consequence.
Diencephalic syndrome in infants: paradoxical emaciation from anterior hypothalamic dysfunction.
Raised ICP signs: headache (worse in morning), vomiting, papilloedema, ↓consciousness, Cushing's triad (late).

Active Recall - Craniopharyngioma (Definition to Clinical Features)

^[1] Senior notes: Adrian Lui Pediatrics Notes.pdf, p. 430 (CNS tumours — clinical presentation) ^[2] Senior notes: Block A - I keep on bumping into people on my side_ pituitary tumours; hypopituitarism.pdf, p. 6 (Craniopharyngiomas section) ^[3] Senior notes: Ryan Ho Neurology.pdf, pp. 161, 166 (Intracranial tumours — clinical approach; pituitary adenoma and apoplexy) ^[4] Senior notes: Maksim Medicine Notes.pdf, p. 105 (Hypothalamus and pituitary disorders — mechanisms of mass effect, differential diagnoses of sellar mass) ^[5] Senior notes: Ryan Ho Ophthalmology.pdf, p. 90 (Papilloedema — pathophysiology and clinical features)

Differential Diagnosis of Craniopharyngioma

The differential diagnosis of craniopharyngioma is really the differential of a sellar/suprasellar mass. You are standing in front of a patient — usually a child with growth failure and visual field defects, or an adult with visual loss and hormonal dysfunction — and the MRI or CT shows a mass in the sellar/suprasellar region. The question is: what is this mass?

The approach is systematic. Think about it by:

Location — is the mass sellar, suprasellar, or both?
Age — child vs adult (different tumour profiles)
Imaging characteristics — calcification, cystic vs solid, enhancement pattern
Hormonal profile — is there hormone hypersecretion, or only deficiency?
Acuity — slow onset vs acute (e.g., pituitary apoplexy)

Differential diagnoses of sellar mass: Pituitary adenoma (MC), Craniopharyngioma (benign tumor from Rathke's pouch, often cystic), Other tumors: pituitary CA (very rare), metastatic tumor (esp. breast), germ cell tumor, lymphoma. Non-neoplastic mass: Rathke cleft cyst, arachnoid cyst ^[4]

Master Differential Diagnosis Table

The table below covers all important differentials of a sellar/suprasellar mass, organised by category, with key distinguishing features and the pathophysiological basis for each. This is the framework an examiner expects you to use.

Differential	Key Features	How to Distinguish from Craniopharyngioma
Pituitary adenoma (most common sellar mass in adults) ^[4]^[6]	Microadenoma ( < 1 cm) vs macroadenoma (≥ 1 cm); functional (70–80%) vs non-functional; usually within sella turcica; adults (3rd–6th decade); rarely calcifies	Hormone hypersecretion (prolactinoma → PRL > 200 ng/mL; GH-secreting → ↑IGF-1; ACTH-secreting → Cushing's). CT: better for calcified tumour (meningioma, craniopharyngioma) — adenomas rarely calcify ^[6]. MRI: solid, enhancing sellar mass. No "machinery oil" cyst.
Meningioma (suprasellar / tuberculum sellae)	Arises from arachnoid cap cells of meninges; typically solid, avidly and homogeneously enhancing; may calcify; dural tail sign; more common in middle-aged women	Homogeneously enhancing solid mass with dural tail. Rarely cystic. Calcification pattern is diffuse/psammomatous (vs. nodular/rim in craniopharyngioma). No endocrine deficiency early on (unless large).
Pituicytoma ^[7]	Very rare; arises from pituicytes (specialized glial cells of posterior pituitary/stalk); solid, enhancing; adults	Extremely rare; solid enhancing stalk/posterior pituitary lesion; no calcification, no cyst

Differential	Key Features	How to Distinguish
Germ cell tumour (germinoma) ^[8]^[9]	Most common intracranial GCT; peak age 10–20 years; classically midline (pineal > suprasellar); can present with DI + hypopituitarism (mimics craniopharyngioma); may secrete AFP (yolk sac elements) or β-hCG	Measurement of AFP and β-hCG in serum and CSF — elevated markers can diagnose NGGCTs without biopsy. Germinoma: typically solid, homogeneously enhancing, NO calcification or cyst (but can engulf pre-existing pineal calcification). Craniopharyngioma: calcified, cystic ^[8]^[9].
Pituitary carcinoma ^[2]	Very rare, primary or secondary; defined by craniospinal or systemic metastasis (cannot be diagnosed by histology alone); typically aggressive clinical course	Diagnosed only by presence of metastasis; extremely rare
Metastatic tumour (esp. breast, lung) ^[4]	Adults with known primary malignancy; rapid onset; diabetes insipidus can be presenting feature (posterior pituitary has direct arterial blood supply → "metastatic trap"); rarely calcifies	History of known malignancy; rapid progression; enhancement pattern is heterogeneous; often involves posterior pituitary/stalk preferentially (because the posterior pituitary has direct arterial supply while the anterior pituitary is supplied via the portal system)
CNS lymphoma (primary)	Typically periventricular, homogeneously enhancing; immunocompromised patients (HIV/AIDS); can involve hypothalamus/pituitary region	Densely enhancing, periventricular location, restricted diffusion on MRI; rapid growth; responds dramatically to steroids (lymphocytes undergo apoptosis — "vanishing tumour"). No calcification.
Chordoma ^[7]	Arises from notochord remnants in clivus; destructive clival mass; adults; can extend to sellar region; bone destruction	Clival origin with bone destruction; characteristic "thumbprint" calcification within myxoid matrix; T2-hyperintense

Differential	Key Features	How to Distinguish
Rathke's cleft cyst ^[4]	Also from Rathke's pouch remnants (same embryological origin as craniopharyngioma!); small, well-demarcated, purely intrasellar or suprasellar cyst; usually asymptomatic (incidental finding in up to 13–33% of autopsies)	Non-enhancing, thin-walled cyst; NO calcification (key distinction from craniopharyngioma); no solid component; cyst fluid is usually mucoid/proteinaceous (T1-hyperintense on MRI) rather than cholesterol-rich "machinery oil". Most are small ( < 1 cm) and asymptomatic.
Arachnoid cyst ^[4]	Congenital; CSF-filled cyst; usually incidental; thin wall, no enhancement, no calcification; follows CSF signal on all MRI sequences	Follows CSF on ALL sequences (T1-hypointense, T2-hyperintense, FLAIR-suppressed); no enhancement, no calcification, no solid component
Dermoid / Epidermoid cyst	Congenital inclusion cysts; dermoid contains fat + hair + skin appendages; epidermoid has pearly white flakes of keratin; can occur in sellar/parasellar region	Dermoid: fat signal on MRI (T1-hyperintense), may show calcification in wall. Epidermoid: restricted diffusion (bright on DWI, differentiates from arachnoid cyst). Neither enhances.

Differential	Key Features	How to Distinguish
Lymphocytic hypophysitis ^[7]	Autoimmune inflammation of pituitary; classically young women (peri-/postpartum); diffusely enlarged, homogeneously enhancing pituitary with thickened stalk; causes hypopituitarism (ACTH deficiency often prominent) and DI	Diffusely enlarged gland (not a focal mass); thickened stalk; peri-/postpartum setting; no calcification. Often associated with other autoimmune diseases. Responds to steroids.
Pituitary abscess ^[7]	Rare; ring-enhancing lesion within pituitary; fever, headache, hypopituitarism; history of sinusitis, meningitis, or prior surgery	Ring enhancement with restricted diffusion (pus); clinical sepsis
Langerhans cell histiocytosis (LCH) ^[8]	Can involve hypothalamic-pituitary axis (infiltration of stalk); DI is the hallmark endocrine feature (25% of CNS LCH); children/young adults; may have systemic features (bone lesions, skin rash)	Thickened, enhancing pituitary stalk ("stalk thickening" differential); associated bony lytic lesions elsewhere; no calcification of the lesion itself
Sarcoidosis / TB granuloma	Granulomatous infiltration of hypothalamus/pituitary; DI + hypopituitarism; systemic features (BHL, skin, liver for sarcoidosis; constitutional symptoms for TB)	Enhancing hypothalamic/stalk thickening; basal meningeal enhancement (TB); systemic clues
Empty sella syndrome ^[6]	Sella appears "empty" on imaging because CSF fills the space and the pituitary is flattened; primary (idiopathic, associated with IIH and obesity) vs secondary (post-surgery/radiation/infarction)	Diagnostic on MRI: sella filled with CSF signal, flattened pituitary at floor; NOT a mass lesion

Differential	Key Features	How to Distinguish
Cavernous/parasellar carotid aneurysm	Pulsatile mass in sellar/parasellar region; can present with CN palsies; potentially catastrophic if biopsied	Flow void on MRI; CTA/MRA diagnostic. MUST be excluded before any biopsy of a sellar mass.
Pituitary apoplexy ^[6]	Sudden haemorrhage into pituitary gland (usually into a pre-existing adenoma); sudden onset excruciating headache + diplopia (CN III pressure) + hypopituitarism (esp. adrenal crisis); neurosurgical emergency	Acute onset (unlike craniopharyngioma which is insidious); CT: hyperdensity (acute blood) in pituitary region; MRI shows haemorrhagic pituitary mass

This is a practical way to prioritise the differential — because the likelihood of each diagnosis shifts dramatically with age.

In children, craniopharyngioma is the most common suprasellar tumour ^[1]^[2]. In adults, pituitary adenoma is the most common cause of sellar mass ^[4]^[7].

Pilocytic astrocytoma (PA) is the most common astrocytoma in children and is classified as Grade 1 (WHO). Classical site is cerebellum but can occur anywhere in CNS including hypothalamus, optic nerve and chiasmal region ^[8]^[9]. When it involves the optic pathway (optic pathway glioma), it closely mimics craniopharyngioma:

Both cause visual loss and endocrine dysfunction in children
Key distinction: optic pathway glioma is strongly associated with NF1 (neurofibromatosis type 1) — look for café-au-lait spots, axillary freckling, neurofibromas ^[3]
On MRI, optic pathway glioma appears as a fusiform enlargement of the optic nerve/chiasm with T2 hyperintensity and enhancement, whereas craniopharyngioma is a cystic/calcified mass separate from the optic structures (displacing rather than thickening them)

When you encounter a sellar/suprasellar mass, the following features help you narrow the differential:

Feature	Craniopharyngioma	Pituitary Adenoma	Rathke Cleft Cyst	Meningioma	Germinoma
Calcification	Very common (50–90%)	Rare	Absent	Present (psammomatous)	Absent
Cystic component	Common (often large)	Uncommon (unless haemorrhagic)	Yes (purely cystic)	Rare	Rare
Enhancement	Solid rim/nodular enhancement	Homogeneous (micro) or heterogeneous (macro)	No enhancement	Avid, homogeneous + dural tail	Homogeneous
Hormone hypersecretion	Never (hormonally inert)	Yes (functioning adenomas)	Never	Never	β-hCG sometimes
Diabetes insipidus at presentation	Common (stalk compression)	Uncommon (rare unless very large)	Rare	Very rare	Common
CT: better for calcified tumour	Yes — CT is the better modality for detecting calcification	Less useful	Not needed	Yes (meningioma, craniopharyngioma) ^[6]	CT less useful

High Yield Exam Point — CT vs MRI for Sellar Masses

CT: better for calcified tumour (meningioma, craniopharyngioma) ^[6]. MRI (contrast, T1-weighted) is the modality of choice for anatomical delineation and surgical planning, but CT is superior for detecting calcification — a key feature that immediately suggests craniopharyngioma (in children) or meningioma (in adults).

If the imaging shows a thickened pituitary stalk rather than a discrete sellar mass, the differential shifts:

Diagnosis	Clues
Langerhans cell histiocytosis	Child; DI; lytic bone lesions; skin rash
Germinoma	Adolescent; DI + hypopituitarism; β-hCG may be elevated
Lymphocytic hypophysitis	Young woman, peri-/postpartum; autoimmune features
Sarcoidosis	BHL on CXR; raised ACE; multi-system
TB	Basal meningitis; constitutional symptoms; Hong Kong endemic
Metastasis	Known primary; rapid onset
Craniopharyngioma (with stalk involvement)	Calcification; cystic component; childhood

Differential by Presenting Feature

Because exam questions often start from a presenting complaint, here is how to think about the differential based on the dominant clinical feature:

"Mechanisms of mass effect — Visual defect: classically bitemporal hemianopia (optic chiasm), but can also be unilateral visual loss (optic nerve) or homonymous hemianopia (optic tract)" ^[4]

Cause	Why
Pituitary macroadenoma	Most common cause of chiasmal compression in adults — the adenoma expands upward out of the sella
Craniopharyngioma	Most common cause in children; presses on chiasm from above or within
Suprasellar meningioma	Tuberculum sellae meningioma compresses chiasm from below/anterior
Optic pathway glioma	Intrinsic expansion of chiasm (children; NF1)
Suprasellar aneurysm	Rare; pulsatile expansion of ICA or ACoA aneurysm

Cause	Why
Craniopharyngioma (stalk compression) ^[2]	Disrupts ADH transport axons
Germinoma (suprasellar)	Infiltrates stalk
LCH	Infiltrates stalk
Metastasis (to posterior pituitary)	Direct arterial blood supply makes it a "metastatic trap"
Lymphocytic hypophysitis	Autoimmune stalk inflammation
Post-surgical / post-traumatic	Iatrogenic stalk damage

Clinical Pearl — DI at Presentation Favours Non-Adenoma Pathology

Pituitary adenomas rarely present with DI (only ~1% even in large macroadenomas) because they usually grow from within the anterior pituitary and push the stalk rather than destroy it. If DI is present at diagnosis, think craniopharyngioma, germinoma, LCH, metastasis, or hypophysitis — NOT pituitary adenoma ^[4]^[6].

Cause	Why
Craniopharyngioma	GH deficiency from pituitary compression — most common suprasellar tumour in children
Optic pathway glioma	Hypothalamic involvement → GH axis disruption
Germinoma	Pituitary/hypothalamic infiltration
Constitutional delay of growth and puberty	Most common cause overall — but NO visual or neurological features
GH deficiency (idiopathic)	Congenital deficiency; no mass on MRI

Why can Rathke's cleft cyst mimic craniopharyngioma? — Because both arise from Rathke's pouch remnants and both are cystic. The critical difference is that Rathke's cleft cyst does NOT calcify, does NOT have a solid enhancing component, and is usually small and asymptomatic.
Why is pituitary adenoma the most common sellar mass in adults but NOT in children? — Pituitary adenomas arise from adenohypophyseal cells that undergo clonal expansion, usually driven by somatic mutations (e.g., GNAS in somatotroph adenomas). These mutations accumulate with age; children's pituitary cells have not had sufficient time for oncogenic mutation accrual. In contrast, craniopharyngioma is embryonic in origin (CTNNB1 mutation present from development), so it manifests early.
Why does DI favour non-adenoma sellar pathology? — The pituitary adenoma grows within the anterior pituitary and pushes structures aside. The posterior pituitary and stalk receive an independent blood supply and are relatively resistant to compression from below. In contrast, craniopharyngioma, germinoma, LCH, and metastases directly infiltrate or compress the stalk/posterior pituitary, interrupting ADH axons.
Why must you exclude a carotid aneurysm before biopsy? — A suprasellar carotid aneurysm can mimic a sellar mass on imaging. If biopsied without pre-operative vascular imaging, catastrophic haemorrhage will result. Always check for flow voids on MRI or perform CTA/MRA before any surgical intervention on a sellar mass.

High Yield Summary — DDx of Craniopharyngioma

The differential is that of a sellar/suprasellar mass.
In children: craniopharyngioma (most common suprasellar tumour), optic pathway glioma (NF1), germinoma, LCH.
In adults: pituitary adenoma (most common), meningioma, craniopharyngioma (2nd peak), metastasis, Rathke's cleft cyst, lymphocytic hypophysitis.
Key distinguishing features of craniopharyngioma: calcification (50–90%) + cystic + childhood + hormonally inert (only deficiency, never secretion).
DI at presentation favours craniopharyngioma, germinoma, LCH, metastasis, or hypophysitis — NOT pituitary adenoma.
Disconnection hyperprolactinaemia (PRL < 100–150): distinguishes stalk compression from a true prolactinoma (PRL typically > 200 in macroadenoma).
CT is better for calcified tumours (meningioma, craniopharyngioma); MRI is the modality of choice for anatomical delineation.
Always exclude vascular lesion (carotid aneurysm) before surgical intervention on any sellar mass.

Active Recall - Craniopharyngioma Differential Diagnosis

References

^[1] Senior notes: Adrian Lui Pediatrics Notes.pdf, p. 430 (CNS tumours — clinical presentation, craniopharyngioma features) ^[2] Senior notes: Block A - I keep on bumping into people on my side_ pituitary tumours; hypopituitarism.pdf, p. 6 (Types of pituitary tumours; craniopharyngiomas) ^[3] Senior notes: Adrian Lui Pediatrics Notes.pdf, p. 148 (NF1, optic pathway glioma) ^[4] Senior notes: Maksim Medicine Notes.pdf, pp. 105–106 (Differential diagnoses of sellar mass; mechanisms of mass effect; hypopituitarism aetiology) ^[5] Senior notes: Maksim Medicine Notes.pdf, p. 278 (Increased ICP; hydrocephalus differential) ^[6] Senior notes: Ryan Ho Endocrine.pdf, pp. 107, 111 (Pituitary adenoma types, diagnosis — CT vs MRI; pituitary apoplexy; acromegaly) ^[7] Senior notes: MBBS Final MB (Surgery) (Felix PY Lai).pdf, p. 1029 (Differential diagnosis of sellar mass — comprehensive list) ^[8] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf, pp. 1258, 1260, 1262 (Pilocytic astrocytoma; germ cell tumours; ependymoma; craniopharyngioma in DDx) ^[9] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf, pp. 530, 532, 534 (Pilocytic astrocytoma; germ cell tumour diagnosis and markers)

Diagnostic Criteria, Diagnostic Algorithm, and Investigations for Craniopharyngioma

Unlike conditions such as diabetes mellitus or rheumatoid arthritis, craniopharyngioma does not have a single set of "diagnostic criteria" with a checklist. The diagnosis is made through the convergence of clinical, radiological, and histopathological findings. Think of it as a three-legged stool — you need all three legs for a confident diagnosis:

Pillar	What It Provides
1. Clinical suspicion	Age-appropriate presentation (growth failure + visual field defect + endocrine dysfunction ± raised ICP), especially in a child
2. Radiological features	Calcified, cystic, suprasellar mass on CT/MRI — this is often sufficient for a strong presumptive diagnosis ^[2]
3. Histopathological confirmation	Definitive: adamantinomatous vs papillary subtype, molecular markers (CTNNB1 / BRAF V600E)

In practice, the combination of calcification on CT + cystic suprasellar mass in a child is so characteristic that experienced neurosurgeons will often proceed to surgery with a presumptive diagnosis of craniopharyngioma before histology returns ^[2]^[10].

High Yield — When Is Histology Mandatory?

Histological confirmation is always the gold standard. However, you must also consider the differential: "Histological diagnosis by surgical biopsy is mandatory if serum and CSF tumour markers are normal" — to differentiate from germinoma, PNETs, ependymoma, LCH, or metastatic disease ^[8]^[9]. If tumour markers (AFP, β-hCG) are elevated, a germ cell tumour may be diagnosed without biopsy.

The diagnostic workup for a suspected craniopharyngioma follows a logical sequence: clinical assessment → imaging → endocrine evaluation → visual assessment → surgical planning → histological confirmation.

Key Principle — Holistic Pituitary Assessment

"For all endocrine investigations, after we realize the posterior pituitary is not good, then cannot stop there — have to check the anterior pituitary hormones as well, holistic plan to not miss anything" ^[11]. Always assess ALL pituitary axes, not just the one that presents clinically.

3. Investigation Modalities — Detailed Breakdown

3.1 Neuroimaging

Imaging is the cornerstone of diagnosis. You need both CT and MRI — they provide complementary information.

Why CT? CT: better for calcified tumour (meningioma, craniopharyngioma) ^[6]. CT is superior for detecting calcification — the radiological hallmark that immediately narrows your differential.

Finding	Appearance	Significance
Calcification	Hyperdense foci (high Hounsfield units) within or at the rim of the mass	Present in ~50–90% of adamantinomatous craniopharyngiomas ^[2]; virtually diagnostic in a child with a suprasellar mass. Papillary subtype rarely calcifies.
Cystic component	Hypodense areas within the mass (lower HU than brain parenchyma, but higher than CSF due to cholesterol/protein content)	The cyst fluid is cholesterol-rich ("machinery oil") — it is NOT pure CSF density
Solid component	Isodense to slightly hyperdense; enhances with contrast	Solid nodular components at the cyst wall or within the lesion
Mass effect	Hydrocephalus (dilated lateral ventricles); midline shift (rare, if very large)	Obstruction of the third ventricle → hydrocephalus ^[2]
Contrast enhancement	Normal brain tissue does not enhance (due to BBB); solid components of craniopharyngioma enhance (they are outside the BBB or have disrupted BBB) ^[3]^[10]	Rim enhancement of cyst wall and enhancement of solid nodules — helps delineate the tumour from surrounding brain

"CT brain ± contrast: Site and multiplicity; Mass effect; Contrast — normal brain tissue does not enhance (due to BBB); enhancement indicates outside BBB or disruption of BBB" ^[3]^[10]

CT windows to use:

Brain window: to assess the mass, cystic components, and surrounding brain parenchyma
Bone window: to assess sellar/sphenoid bone erosion and identify calcification more precisely

MRI is the modality of choice for anatomical delineation and surgical planning ^[2]^[6]. It provides exquisite soft-tissue contrast and multiplanar imaging that CT cannot match.

Sequence	Typical Findings in Craniopharyngioma	Why This Matters
T1-weighted (pre-contrast)	Cystic component: variable signal — can be T1-hyperintense (bright) if cyst fluid is cholesterol-rich/proteinaceous; solid component: isointense to grey matter	T1-hyperintense cyst is characteristic (cholesterol/methhaemoglobin content → paramagnetic shortening of T1). This is unlike an arachnoid cyst which follows CSF signal (T1-hypointense).
T1-weighted (post-Gad)	Solid components and cyst wall enhance; cyst fluid does NOT enhance	Delineates the solid tumour from the cyst; shows relationship to optic chiasm, hypothalamus, pituitary stalk, and vessels
T2-weighted	Cystic component: usually T2-hyperintense (bright); solid component: variable	T2 helps identify the relationship of tumour to hypothalamus (which is also T2-hyperintense) — critical for surgical planning
FLAIR	Cyst fluid does NOT suppress on FLAIR (unlike CSF)	Distinguishes a craniopharyngioma cyst from an arachnoid cyst (arachnoid cyst suppresses on FLAIR because it contains simple CSF)
DWI/ADC	Cyst fluid does NOT show restricted diffusion	Distinguishes from epidermoid cyst (which shows restricted diffusion — bright on DWI) and pituitary abscess (which shows restricted diffusion from pus)
Sagittal thin-cut T1	Shows the pituitary stalk, gland, and optic chiasm in one plane	Essential for surgical planning; shows whether the chiasm is pre-fixed, post-fixed, or in normal position

Key MRI findings to report:

Tumour dimensions (3D measurements)
Relationship to optic chiasm (chiasm displaced? compressed? draped over tumour?)
Relationship to hypothalamus (tumour adherent to hypothalamic floor? invading 3rd ventricle?)
Pituitary stalk (displaced? compressed? not visible?)
Pituitary gland (compressed at floor of sella?)
Hydrocephalus (lateral ventricular dilatation?)
"Pituitary bright spot" on T1-weighted images — normally represents ADH-containing neurosecretory granules in the posterior pituitary. "MRI → bright spot is normally the collection of secretory granules... but for this patient, no longer have pituitary bright spot" ^[11] → absence suggests posterior pituitary dysfunction/DI

Exam Point — Loss of Posterior Pituitary Bright Spot

The normal posterior pituitary appears as a T1-hyperintense "bright spot" on sagittal MRI. This brightness comes from ADH/oxytocin-containing neurosecretory granules (lipid-rich vesicles act as T1-shortening agents). Its absence in a patient with polyuria/polydipsia strongly suggests central diabetes insipidus ^[11].

Seldom done nowadays due to low sensitivity and specificity ^[10]. However, it may show:

Abnormal calcification: tumours, eg. meningioma, craniopharyngioma ^[10]
Sellar enlargement / erosion of posterior clinoid processes (signs of ↑ICP)
In children: widened sutures (raised ICP)

Skull X-ray is now largely replaced by CT and MRI. It is mentioned for completeness and may appear in older-style exam questions.

Not routinely needed for diagnosis but important for surgical planning — to delineate the relationship of the tumour to the circle of Willis, ICA, and anterior cerebral/communicating arteries. Crucial to exclude a suprasellar aneurysm before surgery.

3.2 Endocrine Investigations

A comprehensive pituitary hormone assessment is mandatory — both anterior and posterior pituitary axes must be evaluated ^[4]^[11].

Axis	Tests	Expected Findings in Craniopharyngioma	Explanation
GH axis	Serum IGF-1 (age- and sex-matched reference)	↓IGF-1 for age	GH deficiency is the first axis lost in pituitary compression ^[4]; IGF-1 is the screening test because it has a longer half-life than GH and is less affected by pulsatility/stress ^[2]
Gonadal axis	FSH, LH, oestradiol (F) or testosterone (M)	↓FSH, ↓LH, ↓E2/testosterone (hypogonadotropic hypogonadism)	FSH/LH axis is the second most vulnerable ^[4]
Thyroid axis	TSH, fT4	↓fT4 with ↓/inappropriately normal TSH (secondary hypothyroidism)	In secondary hypothyroidism, TSH may be low, normal, or even mildly elevated (biologically inactive TSH isoforms) — fT4 is the key marker for monitoring ^[4]
Adrenal axis	9 AM cortisol, ACTH	↓cortisol (with ↓/inappropriately normal ACTH) → secondary adrenal insufficiency	Most dangerous deficiency — can cause life-threatening adrenal crisis. Morning cortisol is the screening test.
Prolactin	Serum prolactin	Mildly elevated ( < 100–150 ng/mL) → disconnection hyperprolactinaemia	If prolactin is > 200 ng/mL (> 10× ULN) → suspect prolactinoma, NOT craniopharyngioma ^[2]
Posterior pituitary	Serum Na, serum osmolality, urine osmolality, urine output (24h)	Hypernatraemia, ↑serum osmolality, ↓urine osmolality, ↑urine output → cranial DI pattern	If urine output > 2L/day with dilute urine despite concentrated serum → DI ^[11]^[12]

"Screening → serum insulin-like growth factor (IGF-1) — expected to be above normal for age and gender; much longer half life than serum GH, less affected by other factors (increased stress), better for screening" ^[2]

These are used when basal levels are equivocal or when GH/ACTH deficiency needs confirmation.

Test	Axis Assessed	Principle	Interpretation
Insulin tolerance test (ITT)	GH + ACTH (gold standard for both)	Insulin-induced hypoglycaemia (glucose < 2.2 mmol/L) is a potent stress stimulus → should trigger GH and cortisol release	Adequate response: GH > 3–5 µg/L and cortisol > 500 nmol/L. Failure to rise = deficiency. Contraindicated in epilepsy, IHD, elderly.
Short Synacthen test (SST)	Adrenal (ACTH) axis	Synthetic ACTH (Synacthen/cosyntropin) is given → should stimulate cortisol release if the adrenal glands are functional	Peak cortisol > 500 nmol/L at 30 or 60 min = adequate. BUT: in recent-onset ACTH deficiency (e.g., acute post-surgical), adrenals have not yet atrophied → may give false-normal result (takes 4–6 weeks for adrenal atrophy to develop).
Glucagon stimulation test	GH + ACTH (alternative to ITT)	IM glucagon → raises blood glucose → then rebound hypoglycaemia → stress response → GH and cortisol release	Used when ITT is contraindicated. "Test unreliable in DM patients; glucagon should not be given subcutaneously" ^[13]
GnRH stimulation test	Gonadal axis	IV GnRH → should stimulate FSH/LH release	Blunted response = pituitary hypogonadism; exaggerated response suggests hypothalamic level
TRH stimulation test	Thyroid axis	IV TRH → should stimulate TSH release	Blunted/absent TSH rise = pituitary; delayed/exaggerated rise = hypothalamic. Rarely performed now.

This is used to confirm diabetes insipidus and to distinguish central DI vs nephrogenic DI.

"Water deprivation tests still done quite often, especially when the blood tests don't give much results" ^[11]

Phase	What Happens	What You Measure	Interpretation
Phase 1: Water deprivation (typically 8 hours, or until body weight drops by 3% or serum osmolality > 295)	Patient is deprived of all fluids under close supervision; hourly monitoring of urine volume, urine osmolality, serum osmolality, body weight	Urine osmolality, serum osmolality, urine output	Normal: urine concentrates to > 600 mOsm/kg. DI: urine remains dilute ( < 300 mOsm/kg) despite rising serum osmolality ( > 295)
Phase 2: DDAVP administration (exogenous ADH analogue given after Phase 1 shows DI)	2 µg DDAVP IM/SC or 10–20 µg intranasal	Urine osmolality at 2h post-DDAVP	Central DI: urine osmolality rises > 50% (kidneys can respond to ADH; problem was lack of ADH) → "gave DDAVP → urine osmolarity increases → AVP deficiency that is responsive to DDAVP" ^[11]. Nephrogenic DI: urine osmolality does NOT rise significantly (kidneys cannot respond to ADH).

When to stop the test:

"Body weight is used as a guide, reduction should be less than 3% → if greater than this, stop the test for safety concerns" ^[11]
If serum osmolality rises beyond the reference range
If the patient becomes clinically dehydrated

Copeptin — a newer, safer alternative:

"Copeptin is a surrogate marker for AVP → but AVP half life is too short, so we use this instead" ^[12]
Co-secreted with AVP from the hypothalamic neurons in equimolar amounts, but has a much longer half-life (stable in vitro)
Can be measured in a single blood sample (stimulated by hypertonic saline infusion or arginine infusion)
"Good thing about this marker → can separate nephrogenic and central DI" ^[12]
Avoids the need for prolonged water deprivation (which is "not good — subjects pediatric patients to long periods of water deprivation" ^[12])

Test	Central DI	Nephrogenic DI	Primary Polydipsia
Copeptin (stimulated)	Low ( < 4.9 pmol/L)	High/normal	Low/normal
WDT: urine osmolality after dehydration	Low ( < 300)	Low ( < 300)	High ( > 600)
WDT: response to DDAVP	↑ > 50%	No response	No significant change (already concentrated)

This is essential because bitemporal hemianopia (chiasmal compression) is one of the four classical presentations ^[2].

Test	What It Assesses	Expected Findings	Why
Formal visual field testing (Goldmann or Humphrey perimetry)	Maps the visual field of each eye	Bitemporal hemianopia (loss of temporal fields bilaterally); may be asymmetric; may also show upper temporal quadrantanopia first (because inferior chiasmal fibres from the lower nasal retina cross first and are compressed first by a mass from below)	Chiasmal compression by the suprasellar mass ^[4]
Visual acuity (Snellen chart / LogMAR)	Central acuity	Reduced if optic nerve is directly compressed	Longstanding compression → optic atrophy → irreversible acuity loss
Colour vision (Ishihara plates)	Optic nerve function	Impaired (dyschromatopsia) — an early sign of optic nerve dysfunction	Optic nerve fibres subserving colour are particularly sensitive to compression
Relative afferent pupillary defect (RAPD / Marcus Gunn pupil)	Asymmetry of optic nerve function	Present if one optic nerve is more compressed than the other	Swinging torch test reveals the damaged side
Fundoscopy	Optic disc appearance	Optic atrophy (pale disc) if chronic compression; papilloedema if raised ICP from hydrocephalus	Optic atrophy = direct compression → Wallerian degeneration. Papilloedema = raised ICP transmitted via optic nerve sheath (different mechanism!) ^[5]

"Formal visual field testing (perimetry)" is part of the standard workup for any sellar/suprasellar mass ^[4]^[6].

This is particularly important in the paediatric suprasellar mass differential. Germ cell tumours (especially germinomas) can occur in the suprasellar region and mimic craniopharyngioma.

Marker	When Elevated	Significance
Serum and CSF AFP	Yolk sac tumour elements, immature teratoma	"Elevated AFP levels can be assumed to contain elements of yolk sac tumours or immature teratomas and can effectively rule out pure germinoma" ^[8]^[9]
Serum and CSF β-hCG	Choriocarcinoma elements; mildly elevated in some germinomas	Helps classify the GCT subtype
Both AFP and β-hCG normal	Pure germinoma or mature teratoma — OR non-GCT	"Histological diagnosis by surgical biopsy is mandatory if serum and CSF tumours markers are normal — differentiate pure germinoma and mature teratoma from other intracranial tumours such as PNETs, ependymoma, craniopharyngioma, LCH or metastatic disease" ^[8]^[9]

"Measurement of tumour markers in serum and CSF — both samples should be obtained unless contraindicated. Measurement of AFP and β-hCG is more sensitive in CSF than in serum" ^[8]^[9]

Investigation	Indication	Findings
Bone age (left hand/wrist X-ray)	Children with growth failure	Delayed bone age (reflects GH/thyroid deficiency → delayed skeletal maturation); crucial for assessing remaining growth potential
DEXA scan	Adults; children with longstanding GH/gonadal deficiency	Reduced BMD (GH, oestrogen, testosterone are all bone-protective; their deficiency → osteoporosis)
Lumbar puncture (LP)	If GCT is suspected (for CSF tumour markers); or to measure opening pressure if raised ICP is suspected	"Lumber puncture: detect CSF involvement" ^[1]; CSF AFP/β-hCG; opening pressure; cytology
Genetic/molecular testing on tumour specimen	Post-operatively on resected tissue	CTNNB1 mutation (adamantinomatous) vs BRAF V600E (papillary) — critical for targeted therapy consideration and prognosis
ECG/Echocardiography	Pre-operative assessment; patients on long-term GH or thyroid hormone deficiency	Baseline cardiac function; perioperative risk

Here is how to interpret the investigation results and reach a diagnosis:

Finding	Supports Craniopharyngioma	Alternative Diagnosis to Consider
Calcified cystic suprasellar mass on CT	Very strongly	Meningioma (but usually solid + dural tail); rarely dermoid
T1-hyperintense cyst on MRI	Strongly (cholesterol-rich fluid)	Rathke cleft cyst (but no solid component/calcification)
Loss of posterior pituitary bright spot on MRI	Consistent (stalk involvement → DI)	Germinoma, LCH, metastasis (all can infiltrate stalk)
Multiple pituitary hormone deficiencies	Consistent (mass effect)	Non-functioning pituitary macroadenoma (but no calcification)
Prolactin mildly elevated ( < 100–150)	Consistent (stalk effect)	If PRL > 200 → prolactinoma
Prolactin markedly elevated ( > 200)	Against craniopharyngioma	Prolactinoma (the prolactin level is proportional to tumour size in prolactinomas)
AFP/β-hCG elevated	Against craniopharyngioma	Germ cell tumour
Central DI confirmed on WDT	Consistent (stalk compression/destruction)	Rare in pituitary adenoma; also seen in germinoma, LCH
Bimodal age (child or middle-aged adult)	Consistent	—
Response to dopamine agonist	Against craniopharyngioma	Prolactinoma (tumour shrinks > 50%)

Step	Action	Key Points
1. Suspect	Clinical features — growth failure + VF defect + DI + headache	Think craniopharyngioma in a child with this triad
2. Image	CT (calcification) + MRI (anatomy)	Calcification is the radiological hallmark; MRI for surgical planning
3. Assess hormones	Full pituitary profile + WDT/copeptin	Assess ALL axes — anterior AND posterior
4. Assess vision	Formal perimetry + fundoscopy + acuity	Bitemporal hemianopia; optic atrophy vs papilloedema
5. Exclude GCT	Serum + CSF AFP and β-hCG (in children/adolescents)	Mandatory if markers are normal → biopsy needed
6. Confirm	Histopathology + molecular markers (CTNNB1 vs BRAF V600E)	Gold standard; guides treatment (especially BRAF-targeted therapy)

High Yield Summary — Investigations for Craniopharyngioma

CT: best for detecting calcification (the hallmark — present in 50–90% of adamantinomatous type). CT is better for calcified tumours (meningioma, craniopharyngioma) ^[6].
MRI with contrast: modality of choice for anatomical delineation; look for T1-hyperintense cyst (cholesterol), enhancing solid components, relationship to chiasm/hypothalamus/stalk, loss of posterior pituitary bright spot (DI) ^[11].
Endocrine workup: assess ALL pituitary axes (GH/IGF-1, FSH/LH/sex steroids, ACTH/cortisol, TSH/fT4, prolactin, serum/urine osmolality). Dynamic tests (ITT, SST) for equivocal cases.
Water deprivation test ± copeptin: confirm and classify DI (central vs nephrogenic). Copeptin is a safer, newer alternative ^[12].
Formal visual field testing: bitemporal hemianopia is one of the four classical presentations ^[2].
Tumour markers (AFP, β-hCG): serum AND CSF — mandatory in paediatric suprasellar masses to exclude germ cell tumours ^[8]^[9].
Histopathology: gold standard; CTNNB1 (adamantinomatous) vs BRAF V600E (papillary).
Prolactin level helps distinguish stalk-effect ( < 100–150) from prolactinoma ( > 200 or > 10× ULN) ^[2].

Active Recall - Craniopharyngioma Diagnosis and Investigations

References

^[1] Senior notes: Adrian Lui Pediatrics Notes.pdf, p. 430 (CNS tumours — investigations, lumbar puncture) ^[2] Senior notes: Block A - I keep on bumping into people on my side_ pituitary tumours; hypopituitarism.pdf, pp. 6, 10 (Craniopharyngiomas — radiological findings, classical presentations, diagnosis of pituitary tumours, IGF-1 screening, prolactin interpretation) ^[3] Senior notes: Ryan Ho Neurology.pdf, pp. 32, 162 (Skull X-ray findings, CT brain interpretation for brain tumours — enhancement principles) ^[4] Senior notes: Maksim Medicine Notes.pdf, pp. 105–106 (Mechanisms of mass effect, hypopituitarism investigation — hormonal assay table, MRI and visual field testing) ^[5] Senior notes: Ryan Ho Ophthalmology.pdf, p. 90 (Papilloedema — pathophysiology) ^[6] Senior notes: Ryan Ho Endocrine.pdf, p. 107 (Pituitary adenoma — CT vs MRI; radiological diagnosis) ^[7] Senior notes: MBBS Final MB (Surgery) (Felix PY Lai).pdf, p. 1029 (Differential diagnosis of sellar mass) ^[8] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf, pp. 1260, 1262 (GCT diagnosis — tumour markers, mandatory biopsy indications) ^[9] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf, pp. 532, 534 (GCT diagnosis — AFP, beta-hCG, biopsy) ^[10] Senior notes: Ryan Ho Diagnostic Radiology.pdf, pp. 39–40, 50 (CT interpretation principles, attenuation, enhancement, windowing, MRI in neuroimaging) ^[11] Senior notes: Block A - Two cases of polyuria and polydipsia.pdf, pp. 2–4 (Water deprivation test protocol, DDAVP response, pituitary bright spot, holistic hormonal assessment) ^[12] Senior notes: Chemical Pathology Data interpretation.pdf, p. 1 (Copeptin as surrogate marker for AVP, central vs nephrogenic DI distinction) ^[13] Senior notes: Ryan Ho Chemical Path.pdf, pp. 29, 35–36 (Dynamic function tests — ITT, glucagon test caveats, OGTT)

Management of Craniopharyngioma

Craniopharyngioma management is one of the most challenging problems in neurosurgery and neuro-oncology. The core tension is this: the tumour is histologically benign and slow-growing, but it sits in the most functionally critical real estate in the brain — surrounded by the hypothalamus, optic apparatus, pituitary gland, and major vessels. Aggressive surgery maximises tumour control but risks devastating hypothalamic injury; conservative surgery preserves function but invites recurrence.

The management approach is therefore always multidisciplinary (MDT):

Neurosurgery — surgical resection/CSF diversion
Endocrinology — pre-operative optimisation, lifelong hormone replacement
Ophthalmology — visual monitoring
Radiation Oncology — adjuvant radiotherapy for residual/recurrent disease
Medical Oncology — targeted therapy (BRAF/MEK inhibitors for papillary subtype)
Paediatrics / Paediatric Endocrinology — growth, puberty, neurocognitive support in children
Neuroradiology — imaging surveillance
Psychology / Psychiatry — hypothalamic morbidity, neurocognitive rehabilitation

3. Pre-operative Management

This step is critical and often underappreciated. Operating on a patient with unrecognised adrenal insufficiency can be fatal.

"For all endocrine investigations, after we realize the posterior pituitary is not good, then cannot stop there — have to check the anterior pituitary hormones as well, holistic plan to not miss anything" ^[11]

Axis	Pre-op Action	Why
ACTH/Cortisol axis	Start hydrocortisone if 9 AM cortisol is low or equivocal	This is the MOST DANGEROUS deficiency — anaesthesia and surgical stress demand cortisol. Without replacement → adrenal crisis (hypotension, shock, cardiovascular collapse, death). Even if cortisol appears borderline, err on the side of giving stress-dose steroids perioperatively.
Thyroid axis	Start levothyroxine if fT4 is low	BUT — start AFTER hydrocortisone is given ^[4]. Why? Thyroxine increases metabolic rate → increases cortisol demand. If you give thyroxine to a patient with unrecognised ACTH deficiency, you can precipitate an adrenal crisis.
Gonadal axis	Not urgently replaced pre-op	Can wait until post-operative endocrine reassessment
GH axis	Not replaced pre-op	GH replacement is a long-term consideration, not urgent
ADH (DI)	Start DDAVP if symptomatic DI	Control polyuria and prevent dehydration/hypernatraemia pre-operatively

High Yield — Rule of Hormone Replacement Order

Start hydrocortisone BEFORE thyroxine — always. Giving thyroxine to an ACTH-deficient patient without cortisol cover risks precipitating an Addisonian crisis ^[4]. This is a common exam pitfall.

If the patient presents with acute obstructive hydrocephalus (the tumour blocks the foramen of Monro or 3rd ventricle), this is a neurosurgical emergency:

External ventricular drainage (EVD) — a catheter inserted through a burr hole into the lateral ventricle to drain CSF externally. This is a temporising measure.
VP shunt — ventriculoperitoneal shunt for longer-term CSF diversion
Endoscopic third ventriculostomy (ETV) — creates a new CSF pathway by fenestrating the floor of the 3rd ventricle, bypassing the obstruction. Useful if the obstruction is at the level of the aqueduct or 3rd ventricle.

"CSF shunting for hydrocephalus (eg. in posterior fossa lesions, leptomeningeal meningitis, CSF mets)" ^[14] — the same principle applies here for craniopharyngioma causing 3rd ventricular obstruction.

Timing	Dose	Rationale
Day of surgery	High-dose IV hydrocortisone (e.g., 50–100 mg IV Q6–8h)	Surgical stress markedly increases cortisol demand; the HPA axis is already compromised by the tumour
Post-operative days 1–3	Taper IV hydrocortisone gradually	As stress resolves, reduce to replacement doses
Maintenance	Oral hydrocortisone ~15–20 mg/day (divided doses, larger AM dose)	Lifelong if ACTH deficiency persists

"Hypopituitarism: high dose IV hydrocortisone since the day of surgery" ^[4]

4. Surgical Treatment

Surgery is the primary treatment for craniopharyngioma. The goals are:

Histological diagnosis (definitive confirmation + molecular subtyping)
Tumour removal (maximal safe resection)
Decompression of optic apparatus and relief of mass effect
Relief of hydrocephalus (if present)

Approach	Description	When Used
Transsphenoidal (transnasal endoscopic)	Endoscope passed through the nose → sphenoid sinus → sella. This is the route of choice for sellar/infrasellar tumours ^[2]	Most common approach for craniopharyngiomas with significant intrasellar component; also used for purely suprasellar tumours in the "extended transsphenoidal" (endoscopic endonasal) approach, which accesses the suprasellar space by removing the planum sphenoidale/tuberculum sellae
Transcranial (craniotomy)	Open craniotomy — typically subfrontal, pterional, or interhemispheric approach	"Transfrontal → for those with very large suprasellar extension, severe chiasmal compression" ^[2]; used when the tumour extends significantly lateral, posterior, or into the 3rd ventricle beyond what can be reached transsphenoidally
Combined approach	Both transcranial and transsphenoidal in the same or staged procedures	Very large tumours with both intrasellar and extensive suprasellar/3rd ventricular components

"Transphenoidal → route of choice (transnasal endoscopic / sub-labial)" ^[2] "Transfrontal → for those with very large suprasellar extension, severe chiasmal compression" ^[2]

Why is the transsphenoidal approach preferred when possible?

Avoids brain retraction (the approach goes underneath the brain, not through it)
Lower morbidity than craniotomy
Shorter recovery time
Direct access to the sellar/suprasellar region via a natural corridor (nasal cavity → sphenoid)

The extended endoscopic endonasal approach has revolutionised craniopharyngioma surgery — it provides a wide panoramic view of the sellar/suprasellar region, allows bimanual dissection, and provides excellent visualisation of the optic chiasm, pituitary stalk, and hypothalamus.

Strategy	Definition	Advantages	Disadvantages
Gross total resection (GTR)	Complete removal of all visible tumour	Best tumour control; lowest recurrence rate (10–20% at 10 years)	Higher risk of hypothalamic injury → hypothalamic obesity, neurocognitive deficits, autonomic dysfunction. These are often permanent and devastating, especially in children.
Subtotal resection (STR) + adjuvant RT	Intentional incomplete removal, leaving tumour adherent to hypothalamus, followed by radiotherapy	Preserves hypothalamic function; lower surgical morbidity	Higher recurrence rate without RT (~50–70%); with adjuvant RT, recurrence rate comparable to GTR (~15–25% at 10 years)

Modern consensus (2020s): The pendulum has swung from "GTR at all costs" toward a hypothalamus-sparing, function-preserving strategy — particularly in children. The rationale:

Hypothalamic injury from surgery causes hypothalamic obesity (intractable, leads to metabolic syndrome, cardiovascular morbidity, and dramatically reduced quality of life)
Hypothalamic injury causes neurocognitive dysfunction (memory, executive function, personality changes)
Adjuvant radiotherapy after STR provides comparable long-term tumour control with much less hypothalamic morbidity

"Principle: maximal removal within safety limit; Aim: cytoreduction (↓tumour mass) + functional preservation" ^[14]

Exam Concept — 'Maximum Safe Resection'

In neurosurgery, the concept of 'resection margin' does not apply as it does in extracranial surgery ^[14]. You cannot take a "1 cm margin" when the margin is the hypothalamus or optic nerve. The goal is always maximal safe resection — removing as much tumour as possible while preserving critical neural structures.

Technique	Purpose
Neuronavigation (frameless stereotaxy)	Image-guided surgery for real-time localisation of tumour and critical structures relative to pre-operative MRI ^[14]
Intraoperative MRI	Real-time assessment of residual tumour during surgery (limited availability)
Neurophysiological monitoring (visual evoked potentials)	Monitor optic nerve/chiasm function during dissection to minimise iatrogenic visual loss
Endoscopic visualisation	Panoramic view of the surgical field; excellent for confirming completeness of resection

"Residual / recurrence → especially for macroadenomas; Iatrogenic hypopituitarism / diabetes insipidus" ^[2]

Complication	Mechanism	Management
Diabetes insipidus (most common post-op endocrine complication)	Pituitary stalk damage/transection during surgery → ADH deficiency. Can be transient (stalk oedema) or permanent (stalk transection). A characteristic triphasic response may occur: DI (days 1–3) → SIADH (days 4–8, as stored ADH leaks from damaged neurons) → permanent DI (after day 8)	"DI → SIADH → DI: monitor I/O, Na, urine osmolality daily" ^[4]. Treat with DDAVP; careful fluid balance monitoring
Hypopituitarism	Surgical damage to normal pituitary tissue or remaining stalk	Lifelong hormone replacement (see Section 5 below)
CSF rhinorrhoea (CSF leak through the nose)	Breach of the skull base during transsphenoidal surgery → communication between subarachnoid space and nasal cavity	"CSF rhinorrhoea → will require Abx to prevent ascending meningitis, as well as decision to go back to OT for repair" ^[2]. Diagnose by testing fluid for β2-transferrin (specific marker for CSF). Skull base reconstruction with nasoseptal flap.
Meningitis	Secondary to CSF leak → ascending infection from nasal flora	Prophylactic antibiotics; urgent surgical repair of leak
Visual deterioration	Intraoperative damage to optic nerves/chiasm	Rare with modern techniques; neurophysiological monitoring reduces risk
Post-operative bleeding	Surgical bed haemorrhage	Monitor closely; may require urgent re-operation
Hypothalamic injury	Direct damage during dissection of tumour adherent to hypothalamic floor	Hypothalamic obesity, temperature dysregulation, sleep disturbance, personality changes — often irreversible
Vascular injury	Damage to ICA, anterior cerebral/communicating arteries encased by tumour	Stroke; rare but catastrophic
Seizures	Cortical irritation from transcranial approach	Anticonvulsant prophylaxis/treatment

The Triphasic Response — DI → SIADH → DI

This classic pattern occurs after pituitary stalk damage:

Phase 1 (Day 1–3): DI — axonal shock → no ADH release → polyuria
Phase 2 (Day 4–8): SIADH — dying neurons release stored ADH uncontrollably → water retention, hyponatraemia
Phase 3 (After day 8): Permanent DI — all ADH stores depleted, neurons dead → lifelong DI requiring DDAVP

Not all patients go through all three phases. Some have only transient DI that resolves. Close monitoring of I/O, serum Na, and urine osmolality daily is essential ^[4].

Most patients with craniopharyngioma will require lifelong hormone replacement — either due to the tumour itself or as a consequence of surgery. The regimen follows the same principles as management of hypopituitarism from any cause ^[4].

Axis	Replacement	Key Points
Adrenal (ACTH)	Hydrocortisone ~15–20 mg/day (e.g., 10 mg AM + 5 mg afternoon; or 10 mg + 5 mg + 5 mg)	Avoid nocte dose (risk of insomnia) ^[4]. Must educate patient on sick day rules: double dose during illness/stress to prevent Addisonian crisis. No need for mineralocorticoid (unlike primary adrenal insufficiency — aldosterone is controlled by RAAS, not ACTH).
Thyroid (TSH)	Levothyroxine ~1.6 µg/kg/day	Start AFTER hydrocortisone ^[4]. Monitor with fT4 (NOT TSH — TSH is unreliable in secondary hypothyroidism because the problem is pituitary, so TSH cannot be used as a feedback marker).
Gonadal (FSH/LH)	Depends on gender and fertility wish	Males (no fertility wish): testosterone (e.g., IM Sustanon Q4 weeks). Males (fertility wish): gonadotropins or GnRH (testosterone does not restore spermatogenesis). Females (no fertility wish): combined OCP (E+P). Females (fertility wish): gonadotropins or GnRH ^[4].
GH	Recombinant human GH (rhGH)	In children: critical for linear growth — start after tumour control is confirmed. In adults: improves body composition, bone density, QoL, and lipid profile.
ADH (DI)	DDAVP (desmopressin — synthetic ADH analogue)	Oral, intranasal, or SC/IV. Titrate to urine output. Risk of hyponatraemia from over-replacement — educate patient to have one "breakthrough" episode of dilute urine per day to confirm dose is not excessive.

"Hydrocortisone 20mg/day — avoid nocte (risk of insomnia); stress dose: double dose (risk of Addisonian crisis). Thyroxine 1.6mcg/kg/day — start AFTER hydrocortisone is given (risk of Addisonian crisis). DDAVP." ^[4]

Monitoring in Secondary Hypothyroidism

In secondary (central) hypothyroidism, you monitor fT4, NOT TSH. Why? The problem is in the pituitary — TSH production is already deficient/dysfunctional, so it cannot serve as a reliable feedback signal. A "normal" TSH in this context is meaningless. Aim for fT4 in the upper half of the reference range ^[4].

6. Radiotherapy

Radiotherapy plays an important role as adjuvant treatment after subtotal resection or for recurrent disease.

Residual tumour after planned subtotal resection (the most common indication)
Recurrent craniopharyngioma (after initial surgery)
Unresectable tumour or patient unfit for surgery

Modality	Description	Advantages	Disadvantages
Fractionated external beam RT (EBRT)	Conventional radiotherapy delivered in multiple small fractions (e.g., 50–54 Gy over 25–30 fractions)	Good tumour control (10-year progression-free survival ~70–80% after STR + RT); well-established evidence base	Slow onset of effect (months to years); risk of late effects: hypopituitarism, optic neuropathy, neurocognitive decline, secondary malignancy (especially in children), cerebrovascular disease
Proton beam therapy	Uses protons instead of photons; delivers dose more precisely (Bragg peak — protons deposit most energy at a specific depth, then stop)	Better sparing of surrounding normal tissues (hypothalamus, temporal lobes); lower integral radiation dose to the developing brain — increasingly preferred in children	Limited availability; expensive; similar tumour control to EBRT
Stereotactic radiosurgery (SRS) / Gamma Knife	Single high-dose focused radiation delivered with sub-millimetre precision	"Adjuvant RT (EBRT / stereotactic radiosurgery): if residual mass after resection and histology shows radiosensitive tumour" ^[4]; useful for small, well-defined residual/recurrent solid tumour	NOT suitable for large tumours or those too close to optic apparatus (risk of radiation-induced optic neuropathy if dose to chiasm > 8 Gy in single fraction). Not suitable for cystic tumours (cyst walls may not receive adequate dose).

"± Adjuvant RT (EBRT / SRS e.g. Gamma knife surgery): if persistent disease; can take 10 years to effect" ^[4]

Complication	Time Frame	Mechanism
Hypopituitarism	Months to years (can develop > 10 years post-RT)	Radiation damage to residual pituitary tissue and hypothalamic neurons. GH is the first axis lost (94% at long-term follow-up), then ACTH (43%), then TSH (10%) ^[8]^[9]
Optic neuropathy	Months to years	Radiation-induced microvasculopathy of the optic nerve → progressive visual loss. Risk increases if dose to optic apparatus > 54 Gy (EBRT) or > 8 Gy (SRS single fraction)
Neurocognitive decline	Years	Radiation damage to white matter and hippocampi; particularly devastating in young children (developing brain is more radiosensitive)
Cerebrovascular disease	Years to decades	Radiation-induced vasculopathy → ↑risk of stroke, Moyamoya syndrome (especially in children)
Secondary malignancy	Decades	Radiation-induced neoplasm in the irradiated field (e.g., glioma, meningioma); risk is small but not negligible, especially in children with long life expectancy ahead

7. Targeted Systemic Therapy — The New Frontier

This is one of the most exciting developments in craniopharyngioma management and represents the translation of molecular understanding into clinical practice.

Background: Papillary craniopharyngiomas harbour the BRAF V600E mutation (the same mutation found in melanoma, papillary thyroid cancer, and hairy cell leukaemia). This mutation constitutively activates the RAS–RAF–MEK–ERK signalling cascade, driving cell proliferation.

Drug	Target	Mechanism
Vemurafenib / Dabrafenib	BRAF V600E kinase	Directly inhibits the mutant BRAF protein → blocks the MEK–ERK cascade → ↓cell proliferation and ↑apoptosis
Trametinib / Cobimetinib	MEK1/2 kinase	Inhibits the downstream MEK kinase → synergistic with BRAF inhibitor; reduces resistance

Evidence: Case reports and small series have demonstrated dramatic tumour shrinkage with dabrafenib + trametinib or vemurafenib in recurrent/progressive papillary craniopharyngioma. The combination of BRAF + MEK inhibitor is now standard (monotherapy with BRAF inhibitor alone can lead to paradoxical MAPK activation and resistance).

Clinical use:

Neoadjuvant (before surgery): shrink the tumour to make resection safer and more complete
Primary therapy: for unresectable or recurrent papillary craniopharyngioma
Not applicable to adamantinomatous subtype (no BRAF V600E mutation)

Adamantinomatous craniopharyngiomas harbour CTNNB1 mutations (activating the Wnt/β-catenin pathway). Targeted inhibition of this pathway is under active research but no FDA/EMA-approved targeted therapy exists yet for this subtype. Investigational approaches include:

MEK inhibitors (some downstream cross-talk with Wnt pathway)
Wnt pathway inhibitors (preclinical)
Immune checkpoint inhibitors (early trials)

For predominantly cystic craniopharyngiomas (especially in children where minimising surgical morbidity is paramount):

Agent	Mechanism	How Administered	Limitations
Bleomycin	Cytotoxic antibiotic; causes DNA strand breaks in cyst wall lining cells → cyst wall sclerosis → prevents cyst re-accumulation	Ommaya reservoir (subcutaneous catheter placed into the cyst) → intermittent intracystic instillation	Risk of leakage into surrounding brain → severe neurotoxicity (including hypothalamic damage, optic neuropathy). Largely fallen out of favour.
Interferon-alpha	Antiproliferative, anti-angiogenic, immunomodulatory effects on cyst wall epithelium	Ommaya reservoir → intracystic instillation	Better safety profile than bleomycin; used in selected centres
Phosphorus-32 (³²P)	Beta-emitting radioisotope; delivers localised radiation to the cyst wall	Intracystic instillation	Requires nuclear medicine expertise; risk of radiation damage if cyst wall is thin and agent leaks

When to consider intracystic therapy:

Large cystic component causing visual compromise or raised ICP → urgent decompression by cyst aspiration (via Ommaya reservoir), followed by intracystic agent to prevent rapid re-accumulation
Bridge to definitive surgery or radiotherapy
Palliative in patients unfit for surgery

9.1 Hypothalamic Obesity

This is the most devastating and treatment-resistant complication. It results from damage to the ventromedial hypothalamus (satiety centre) and disruption of leptin/insulin signalling pathways:

Intervention	Mechanism	Evidence
Dietary modification + exercise	Caloric restriction and energy expenditure	Limited efficacy — the hypothalamic drive to eat overrides voluntary restraint
GH replacement	GH is lipolytic; its deficiency contributes to fat accumulation	Partial benefit; does not fully reverse obesity
Stimulant medications (dextroamphetamine)	↑catecholamines → ↑energy expenditure, ↓appetite	Small studies show modest benefit
GLP-1 receptor agonists (semaglutide, liraglutide)	Mimic incretin signalling → ↓appetite, ↓gastric emptying	Emerging evidence; promising but not standard yet
Bariatric surgery	Mechanical restriction ± malabsorption	Case series show variable results; risk-benefit must be individualised
Prevention (most important!)	Hypothalamus-sparing surgical strategy	The best treatment is avoidance — STR + RT is preferred over aggressive GTR if hypothalamic invasion is present

Craniopharyngioma has a significant recurrence rate (overall ~20–40% at 10 years) regardless of initial treatment. Lifelong surveillance is mandatory.

Modality	Frequency	Purpose
MRI pituitary/brain with contrast	Every 3–6 months for the first 2–3 years, then annually for at least 10 years, then every 2–3 years lifelong	Detect recurrence early
Pituitary hormone profile	At least annually (more frequently in the first year post-treatment)	Detect new or progressive hormone deficiencies (can develop years after RT)
Formal visual field testing	At least annually	Detect visual deterioration from recurrence or post-RT optic neuropathy
Growth monitoring (children)	Every 3–6 months	Assess response to GH replacement; detect recurrence (growth arrest)
Neurocognitive assessment (children)	Baseline + periodically	Detect neurocognitive decline (hypothalamic injury, RT effects)
Bone density (DEXA)	Every 2–3 years (adults)	Monitor for osteoporosis (GH, gonadal, thyroid deficiency)
Metabolic monitoring	Annually	BMI, glucose, lipid profile (hypothalamic obesity, GH deficiency → metabolic syndrome)

Modality	Role	Key Indications
Surgery (1st line)	Primary treatment	All craniopharyngiomas causing symptoms/compression; histological diagnosis; decompression
Hormone replacement	Essential supportive care	Lifelong for all pituitary deficiencies; hydrocortisone first, then thyroxine
Radiotherapy	Adjuvant after STR; for recurrence	Residual tumour post-STR; recurrent disease; unresectable tumour
BRAF ± MEK inhibitors	Targeted therapy for papillary subtype	BRAF V600E-mutant papillary craniopharyngioma (neoadjuvant, unresectable, or recurrent)
Intracystic therapy	Cyst control	Predominantly cystic tumours; bridge to surgery/RT; palliative
CSF diversion	Emergency	Acute obstructive hydrocephalus

High Yield Summary — Management of Craniopharyngioma

Surgery is the primary treatment — the approach is transsphenoidal (route of choice) for sellar/infrasellar tumours; transcranial for very large suprasellar extension or severe chiasmal compression ^[2].
Maximum safe resection — the goal is to remove as much tumour as safely possible while preserving hypothalamic and optic function. The concept of resection margin does not apply in neurosurgery ^[14].
GTR vs STR + RT: modern approach favours hypothalamus-sparing STR + adjuvant RT if tumour is adherent to hypothalamus. Hypothalamic morbidity from aggressive surgery is often worse than the tumour itself.
Pre-op cortisol replacement is mandatory — start hydrocortisone BEFORE thyroxine (risk of Addisonian crisis) ^[4].
Post-op monitoring: watch for triphasic DI response (DI → SIADH → DI) — monitor I/O, Na, urine osmolality daily ^[4].
CSF rhinorrhoea: test for β2-transferrin; requires antibiotics and possible surgical repair ^[2].
Lifelong hormone replacement: hydrocortisone, levothyroxine (monitor fT4 not TSH), sex steroids ± gonadotropins, GH, DDAVP ^[4].
BRAF + MEK inhibitors (dabrafenib + trametinib): transformative for BRAF V600E-mutant papillary craniopharyngioma — dramatic tumour shrinkage reported.
Radiotherapy: fractionated EBRT, proton beam (children), or stereotactic radiosurgery for residual/recurrent disease.
Surveillance is lifelong — MRI, hormones, visual fields, growth (children), neurocognitive assessment.

Active Recall - Craniopharyngioma Management

References

^[2] Senior notes: Block A - I keep on bumping into people on my side_ pituitary tumours; hypopituitarism.pdf, pp. 6, 11 (Craniopharyngioma presentations; surgical approach — transsphenoidal vs transfrontal; indications for surgery; complications — CSF rhinorrhoea, DI, hypopituitarism, postoperative bleeding; prolactinoma medical treatment) ^[4] Senior notes: Maksim Medicine Notes.pdf, pp. 105–108 (Hypopituitarism management — hydrocortisone before thyroxine, DDAVP, sex hormones, stress dosing; TSS complications — DI-SIADH-DI, CSF rhinorrhoea, hypopituitarism; adjuvant RT; acromegaly management; monitoring) ^[8] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf, pp. 1261–1262 (Radiotherapy complications — GH 94%, ACTH 43%, TSH 10%; medulloblastoma treatment principles applicable to RT) ^[9] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf, pp. 534 (RT complications — endocrine abnormalities, cerebrovascular disease) ^[11] Senior notes: Block A - Two cases of polyuria and polydipsia.pdf, pp. 2–4 (Holistic hormonal assessment principle; DDAVP response) ^[14] Senior notes: Ryan Ho Neurology.pdf, pp. 163 (Management of brain tumours — medical therapy, surgical approach, stereotactic biopsy, maximal safe resection, CSF shunting, operative techniques, post-op complications)

Complications of Craniopharyngioma

Complications of craniopharyngioma arise from three sources: the tumour itself (mass effect), the treatment (surgery, radiotherapy), and the long-term sequelae of pituitary/hypothalamic dysfunction. In practice, it is the treatment-related complications — particularly hypothalamic injury — that dominate the clinical picture and determine long-term quality of life. Understanding the "why" behind each complication is essential.

These are the consequences of a growing mass in the sellar/suprasellar region, compressing the structures we discussed in the anatomy section.

Complication	Pathophysiology	Clinical Consequence
Hypopituitarism	Direct compression of the anterior pituitary gland and/or pituitary stalk by the expanding mass → progressive loss of hormone-producing cells and disruption of hypothalamic releasing/inhibiting hormone delivery via the portal system	Order of loss: GH → FSH/LH → ACTH → TSH ^[4]. In children, GH deficiency manifests as growth failure; gonadotropin deficiency prevents puberty. ACTH deficiency can lead to life-threatening adrenal crisis.
Diabetes insipidus	Compression of the pituitary stalk → disruption of ADH-carrying axons from the supraoptic and paraventricular nuclei to the posterior pituitary ^[2]	Polyuria, polydipsia, nocturia; if untreated → severe dehydration and hypernatraemia
Visual loss	Chiasmal compression → bitemporal hemianopia; progressive compression → optic atrophy → irreversible blindness ^[2]	"Vision Loss/Visual Field Deficits" is one of the primary indications for surgical intervention ^[2]. If untreated, permanent optic nerve damage occurs.
Obstructive hydrocephalus	Obstruction of the third ventricle (or foramen of Monro) by the tumour → CSF cannot flow from the lateral ventricles through the 3rd ventricle to the aqueduct → progressive ventricular dilatation → raised ICP ^[2]	Headache, vomiting, papilloedema, ↓consciousness, Cushing's triad (late), brain herniation. This is a neurosurgical emergency requiring CSF diversion.
Hypothalamic dysfunction	Direct tumour invasion or compression of the hypothalamus — particularly the ventromedial hypothalamus (satiety centre), thermoregulatory centres, and sleep-wake centres	Hypothalamic obesity, temperature dysregulation, sleep disturbance, personality/behavioural changes, memory impairment. Can occur pre-operatively if tumour invades the hypothalamus.

Why Is Hydrocephalus Dangerous?

The cranial vault is a fixed-volume box containing brain (~80%), blood (~10%), and CSF (~10%) — the Monro-Kellie doctrine. When CSF outflow is obstructed, CSF volume rises, and because total volume is fixed, ICP rises. Unchecked ICP rise → cerebral perfusion pressure falls (CPP = MAP − ICP) → cerebral ischaemia → brain herniation → death. This is why acute hydrocephalus requires emergency CSF diversion (EVD or VP shunt or ETV) ^[15].

2. Complications of Surgical Treatment

Surgery is the primary treatment, but operating in the sellar/suprasellar region carries specific risks because of the intimate anatomical relationships.

"Disadvantages: Residual / recurrence → especially for macroadenomas; Iatrogenic hypopituitarism / diabetes insipidus. Acute complication: Postoperative bleeding; CSF rhinorrhea → will require Abx to prevent ascending meningitis, as well as decision to go back to OT for repair" ^[2]

Complication	Incidence	Mechanism	Management
Iatrogenic diabetes insipidus	~80–90% transiently; 40–80% permanently (highest among all pituitary region tumours)	Pituitary stalk transection or devascularisation during tumour dissection → ADH axons interrupted. The stalk is almost always involved by craniopharyngioma, making preservation extremely difficult.	DDAVP (desmopressin). Monitor I/O, serum Na, urine osmolality daily. Watch for the triphasic response (DI → SIADH → DI) ^[4].
Iatrogenic hypopituitarism	~50–90% (partial or complete)	Damage to residual normal pituitary tissue during resection + stalk damage disrupting hypothalamic-pituitary axis	"Hypopituitarism: high dose IV hydrocortisone since the day of surgery" ^[4]. Lifelong hormone replacement: hydrocortisone → levothyroxine → sex steroids → GH → DDAVP.
Triphasic DI–SIADH–DI response	Variable	Phase 1 (days 1–3): axonal shock → no ADH release → DI. Phase 2 (days 4–8): dying neurons release stored ADH uncontrollably → SIADH → hyponatraemia. Phase 3 (day > 8): all ADH stores depleted, neurons dead → permanent DI.	"DI → SIADH → DI: monitor I/O, Na, urine osmolality daily" ^[4]. During SIADH phase: fluid restriction, withhold DDAVP. Severe hyponatraemia: hypertonic saline with extreme caution.
Adrenal crisis (Addisonian crisis)	Perioperative or early postoperative	If ACTH deficiency is not recognised/treated perioperatively → cortisol nadir during surgical stress → cardiovascular collapse	Prevention: high-dose IV hydrocortisone perioperatively. Treatment: IV hydrocortisone 100 mg bolus + IV fluids + glucose.

Hyponatraemia — A Common Post-operative Pitfall

Post-operative hyponatraemia is extremely common after transsphenoidal surgery (~30%). It can be caused by: (1) SIADH (phase 2 of the triphasic response), (2) cerebral salt wasting, or (3) excessive DDAVP dosing. The clinical consequences of unrecognised hyponatraemia include seizures, cerebral oedema, and death. If chronic hyponatraemia is corrected too rapidly, it can cause central pontine myelinolysis (osmotic demyelination syndrome) — "patients become tetraplegic" ^[16]. The safe rate of correction is < 10–12 mmol/L/day (ideally < 8 mmol/L/day) ^[16].

Complication	Mechanism	Details
Visual deterioration	Intraoperative damage to the optic nerves or chiasm (from retraction, cauterisation, or direct injury during tumour dissection)	Risk ~5–10%; neurophysiological monitoring (visual evoked potentials) reduces this risk. The optic chiasm is often draped over the tumour, making it vulnerable.
Postoperative bleeding	Haemorrhage from the tumour bed, surgical site, or surrounding vessels	"Postoperative bleeding" ^[2] — can cause acute raised ICP or compressive haematoma. May require urgent re-operation.
Vascular injury / stroke	Damage to the ICA, ACA, ACoA, or perforating arteries encased by the tumour	Rare but catastrophic. More common with large tumours encasing the circle of Willis. Presents as focal neurological deficit (hemiparesis, aphasia).
Frontal lobe injury (transcranial approach)	Brain retraction during subfrontal or pterional craniotomy	Personality changes, anosmia (olfactory nerve compression), cognitive decline
Seizures	Cortical irritation from craniotomy (transcranial approach); uncommon in transsphenoidal	Anticonvulsant treatment (e.g., levetiracetam); usually not for primary prophylaxis unless seizures occur ^[14]

Complication	Mechanism	Management
CSF rhinorrhoea → meningitis	Breach of the skull base during transsphenoidal approach → communication between subarachnoid space and nasal cavity → ascending infection from nasal flora (S. pneumoniae, H. influenzae, S. aureus)	"CSF rhinorrhea → will require Abx to prevent ascending meningitis, as well as decision to go back to OT for repair" ^[2]. Diagnose with β2-transferrin test ^[4]. Treat with prophylactic antibiotics + surgical repair (nasoseptal flap reconstruction).
Wound infection (transcranial approach)	Bacterial contamination of surgical wound	Antibiotics; wound care

"CSF rhinorrhoea: test fluid for beta transferrin" ^[4] — β2-transferrin is virtually specific to CSF (it is produced by neuraminidase in the CNS and is not found in nasal secretions, tears, or blood). A positive test confirms the leak is CSF.

Radiotherapy is used adjuvantly after subtotal resection or for recurrence. Its complications are predominantly late effects and are particularly concerning in children.

"Radiotherapy complications: Ototoxicity; Short stature (↓ GH); Endocrine abnormalities (↓ GH (94%)/ ACTH (43%)/ TSH (10%)); Cerebrovascular abnormalities (Stroke/ Intracranial hemorrhage)" ^[8]^[9]

Complication	Time Course	Mechanism	Clinical Details
Radiation-induced hypopituitarism	Months to > 10 years post-RT	Radiation damage to hypothalamic neurons and residual pituitary tissue → progressive hormone loss. The hypothalamus is more radiosensitive than the pituitary gland itself.	GH is lost first (94%) → growth failure in children if not on replacement. ACTH next (43%) → risk of adrenal crisis years after RT. TSH last (10%) ^[8]^[9]. Lifelong annual endocrine surveillance is mandatory because new deficiencies can appear decades later.
Optic neuropathy	6 months to 3 years	Radiation-induced microvasculopathy of the optic nerve → ischaemic optic neuropathy → progressive irreversible visual loss	Risk increases if dose to optic apparatus > 54 Gy (fractionated) or > 8 Gy (single-fraction SRS). This is the reason SRS is contraindicated for tumours abutting the optic chiasm.
Neurocognitive decline	Years	Radiation damage to cerebral white matter, hippocampi, and developing neural circuits → ↓processing speed, ↓memory, ↓executive function	"Craniospinal radiation is avoided or delayed in children due to severe toxicity to the rapidly developing CNS such as neurocognitive impairment" ^[8]^[9]. Proton beam therapy reduces dose to surrounding brain and is increasingly preferred in children for this reason.
Cerebrovascular disease	Years to decades	Radiation vasculopathy — endothelial damage → intimal fibrosis → progressive large-vessel stenosis (Moyamoya-like syndrome), small-vessel disease, and vessel wall fragility	"Cerebrovascular abnormalities (Stroke/ Intracranial hemorrhage)" ^[8]^[9]. Children are at higher risk. Screening with MRA may be warranted.
Secondary malignancy	Decades	Radiation-induced DNA damage in normal cells within the radiation field → de novo malignant transformation (radiation-induced glioma, meningioma, sarcoma)	Risk is small (~2–5% at 20 years) but significant in children who have decades of life ahead. Another argument for proton beam therapy (lower integral dose).

4. Hypothalamic Morbidity — The Most Devastating Long-term Complication

Hypothalamic morbidity deserves its own section because it is the defining long-term complication that separates craniopharyngioma from other pituitary tumours. Pituitary adenomas rarely invade the hypothalamus; craniopharyngiomas (especially adamantinomatous type) are frequently firmly adherent to the hypothalamic floor, and surgical dissection in this area causes irreversible damage.

Feature	Detail
Incidence	50–75% of patients post-operatively (higher with GTR than STR)
Mechanism	Damage to the ventromedial hypothalamus (VMH, the "satiety centre") → loss of satiety signalling → hyperphagia. Also: damage to hypothalamic leptin/insulin receptor signalling → ↓energy expenditure + ↑lipogenesis + ↑insulin resistance. Additional contribution from GH deficiency (GH is lipolytic) and reduced physical activity.
Clinical picture	Rapid, relentless weight gain over months post-surgery, often progressing to morbid obesity (BMI > 40). Extremely resistant to dietary and exercise interventions because the central satiety mechanism is destroyed. Associated with metabolic syndrome (T2DM, dyslipidaemia, fatty liver, cardiovascular disease).
Why is it so difficult to treat?	The problem is not "willpower" — the hypothalamic damage fundamentally alters the energy balance set-point. The brain "believes" the body is starving and drives compulsive eating while simultaneously reducing metabolic rate.
Prevention	Hypothalamus-sparing surgery — this is the strongest argument for planned STR + RT rather than aggressive GTR when the tumour is adherent to the hypothalamus. Once hypothalamic damage occurs, it is irreversible.

Complication	Mechanism
Temperature dysregulation	Damage to the anterior hypothalamus (preoptic area — heat dissipation centre) → poikilothermia or hyperthermia; damage to posterior hypothalamus → hypothermia. Patients may have episodic fever or inability to regulate body temperature with ambient changes.
Sleep disturbance	Damage to the suprachiasmatic nucleus (master circadian clock) and other sleep-regulatory centres (VLPO, orexin/hypocretin neurons) → excessive daytime somnolence, disturbed sleep-wake cycle, narcolepsy-like syndrome
Neurobehavioural / psychiatric	Damage to hypothalamic-limbic connections → emotional lability, rage attacks, apathy, depression, social withdrawal, personality changes. Devastating in children — affects school performance and social development.
Memory impairment	Damage to the mammillary bodies or fornix (components of the Papez circuit — the neural circuit for memory consolidation: hippocampus → fornix → mammillary bodies → anterior thalamic nuclei → cingulate gyrus → hippocampus)
Autonomic dysfunction	Disruption of hypothalamic autonomic centres → orthostatic hypotension, tachycardia, abnormal sweating, GI dysmotility
Diencephalic syndrome (infants)	"Craniopharyngioma: arise in suprasellar region → VF defect, hypopituitarism, diencephalic syndrome" ^[1] — paradoxical emaciation (failure to thrive despite adequate caloric intake) + hyperalertness + euphoria. Caused by anterior hypothalamic dysfunction. This is seen pre-operatively in infants.

Why Hypothalamic Obesity Is the 'Price of Cure'

Historically, neurosurgeons pursued gross total resection to minimise recurrence. While recurrence rates were indeed lower, long-term follow-up revealed that patients with hypothalamic damage from surgery had worse functional outcomes and quality of life than those with residual tumour managed by STR + RT. This has fundamentally shifted the surgical philosophy from "radical cure" to "functional preservation." The hypothalamus cannot regenerate.

Feature	Detail
Incidence	Overall ~20–40% at 10 years (GTR: ~10–20%; STR alone without RT: ~50–70%; STR + RT: ~15–25%)
Timing	Most recurrences occur within the first 5 years, but late recurrences (> 10 years) are well-documented → lifelong surveillance required
Risk factors	Subtotal resection without adjuvant RT; adamantinomatous subtype (more infiltrative, more adherent); younger age at diagnosis
Detection	Serial contrast MRI; clinical deterioration (new visual symptoms, endocrine dysfunction, headache)
Management	Re-operation ± radiotherapy (if not previously given); intracystic therapy for cystic recurrence; BRAF ± MEK inhibitors for BRAF V600E-mutant papillary recurrence

"Residual / recurrence → especially for macroadenomas" ^[2] — while this lecture point refers to pituitary adenomas, the principle applies equally (or even more) to craniopharyngiomas, which are notorious for their adherence and recurrence.

If hydrocephalus requires a permanent VP shunt, there are specific shunt-related complications:

From ^[15]:

Complication	Mechanism	Details
Shunt blockage (most common mechanical failure)	Choroid plexus, brain parenchyma, protein, or tumour cells obstruct the catheter	"80% proximal block, 10% valve, 10% distal block" ^[15]. Presents with recurrence of raised ICP symptoms. Ix: urgent CT brain + shunt series (plain XR of entire shunt: skull XR, C-spine XR, CXR, AXR) ^[15]. Mx: neurosurgical shunt revision.
Shunt infection (most serious)	Contamination during surgery or haematogenous seeding; pathogens: S. epidermidis, S. aureus ^[15]	"Fever, lethargy, meningism, S/S of raised ICP" ^[15]. Ix: contrast CT brain, inspect shunt course for cutaneous erythema. Mx: antibiotics + shunt removal/revision ± temporary EVD.
Overshunting	Excessive CSF drainage → ↓ICP below normal	"Postural headache (worsened with standing/sitting, relieved when lying down). Can lead to subdural haematoma (stretching of bridging veins)" ^[15]. Programmable valves allow adjustment of drainage rate.
Distal catheter complications	Peritoneal end of VP shunt	Inguinal hernia, perforated abdominal viscus/peritonitis, intraperitoneal CSF-filled pseudocyst, tumour seeding ^[15]

Complication	Mechanism	Clinical Impact
Growth failure (children)	GH deficiency from tumour and/or treatment (surgery/RT)	Requires lifelong GH replacement; final adult height depends on timing of diagnosis and treatment
Pubertal delay / infertility	FSH/LH deficiency → hypogonadotropic hypogonadism	Requires sex steroid replacement; fertility possible with gonadotropin therapy if desired ^[4]
Osteoporosis	GH deficiency + hypogonadism + hypothyroidism all contribute to ↓bone density	DEXA screening; bisphosphonates if indicated; hormone replacement is protective
Cardiovascular morbidity	Hypothalamic obesity → metabolic syndrome (T2DM, dyslipidaemia, HTN); GH deficiency → adverse lipid profile and endothelial dysfunction; hypocortisolism if under-replaced	Leading cause of premature death in craniopharyngioma survivors
Psychosocial / Quality of Life	Hypothalamic injury → obesity, sleep disturbance, personality changes; visual impairment; lifelong medication burden; school/work disruption	Craniopharyngioma survivors report significantly reduced QoL compared to other brain tumour survivors. Psychological support is essential.
Water/electrolyte emergencies	Permanent DI → risk of dehydration/hypernatraemia if DDAVP is missed; DDAVP over-replacement → hyponatraemia	Patient/family education is critical: carry emergency ID, "sick day rules" for cortisol, access to DDAVP at all times

Category	Key Complications
Tumour itself	Hypopituitarism, DI, visual loss, hydrocephalus, hypothalamic dysfunction
Surgery	DI (most common), hypopituitarism, CSF rhinorrhoea (→ meningitis), postoperative bleeding, vascular injury/stroke, hypothalamic injury (→ obesity), visual deterioration
Radiotherapy	Hypopituitarism (GH 94%, ACTH 43%, TSH 10%), optic neuropathy, neurocognitive decline, cerebrovascular disease (Moyamoya), secondary malignancy
CSF shunt	Blockage, infection (S. epidermidis, S. aureus), overshunting (→ SDH), distal catheter complications
Long-term	Hypothalamic obesity (most devastating), growth failure, infertility, osteoporosis, cardiovascular disease, psychosocial morbidity

High Yield Summary — Complications of Craniopharyngioma

Hypothalamic obesity is the single most devastating complication — caused by surgical damage to the ventromedial hypothalamus (satiety centre); intractable, irreversible, and the strongest argument for hypothalamus-sparing surgery (STR + RT).
Diabetes insipidus is the most common post-operative endocrine complication; watch for the triphasic response (DI → SIADH → DI) — monitor I/O, Na, urine osmolality daily ^[4].
Post-operative hyponatraemia is very common (~30%); causes include SIADH, cerebral salt wasting, or DDAVP over-dosing. Too-rapid correction of chronic hyponatraemia causes central pontine myelinolysis ("patients become tetraplegic") ^[16].
CSF rhinorrhoea: diagnose with β2-transferrin; treat with antibiotics + surgical repair to prevent ascending meningitis ^[2]^[4].
Radiotherapy complications: GH lost first (94%), ACTH (43%), TSH (10%); also optic neuropathy, neurocognitive decline, cerebrovascular disease (Moyamoya), and secondary malignancy ^[8]^[9].
Shunt complications: blockage (most common — 80% proximal), infection (S. epidermidis, S. aureus — most serious), overshunting (→ SDH) ^[15].
Long-term: growth failure, infertility, osteoporosis, cardiovascular morbidity, psychosocial dysfunction — all require lifelong MDT follow-up.
Prevention is key: hypothalamus-sparing surgery, adequate perioperative steroid cover, proton beam RT in children to minimise late effects.

Active Recall - Craniopharyngioma Complications

References

^[1] Senior notes: Adrian Lui Pediatrics Notes.pdf, p. 430 (CNS tumours — craniopharyngioma causing VF defect, hypopituitarism, diencephalic syndrome) ^[2] Senior notes: Block A - I keep on bumping into people on my side_ pituitary tumours; hypopituitarism.pdf, pp. 4, 11 (Panhypopituitarism due to craniopharyngioma; surgical complications — residual/recurrence, iatrogenic hypopituitarism/DI, postoperative bleeding, CSF rhinorrhoea → meningitis) ^[4] Senior notes: Maksim Medicine Notes.pdf, pp. 106–108 (Hypopituitarism management; TSS complications — DI → SIADH → DI, CSF rhinorrhoea with beta transferrin, hypopituitarism with IV hydrocortisone; hormone replacement order and monitoring) ^[8] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf, pp. 1262, 1264 (Radiotherapy complications — ototoxicity, short stature, endocrine abnormalities with frequencies, cerebrovascular abnormalities) ^[9] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf, pp. 534 (Radiotherapy complications — GH 94%, ACTH 43%, TSH 10%, cerebrovascular disease) ^[14] Senior notes: Ryan Ho Neurology.pdf, pp. 163, 165 (Brain tumour management — anticonvulsants, glucocorticoids, surgical principles, post-op complications) ^[15] Senior notes: Maksim Surgery Notes.pdf, p. 360 (CSF shunt complications — blockage, infection, overshunting, distal catheter complications; shunt series investigation) ^[16] Senior notes: Block A - Electrolyte and Acid-Base Disorders.pdf, p. 22 (Hyponatraemia correction rate; central pontine myelinolysis — "patients become tetraplegic")

High Yield Summary

Craniopharyngioma = benign (WHO Grade I) tumour from Rathke's pouch remnants, most common suprasellar tumour in children.
Two subtypes: Adamantinomatous (CTNNB1 mutation, children, calcified, "machinery oil" cyst, adherent) vs Papillary (BRAF V600E, adults, rarely calcified, better demarcated).
Calcified suprasellar mass in a child = craniopharyngioma until proven otherwise.
Four classical presentations: (1) Hypopituitarism → growth retardation; (2) Pituitary stalk compression → DI; (3) Chiasmal compression → bitemporal hemianopia; (4) Third ventricle obstruction → hydrocephalus.
Stalk compression causes both DI (ADH axon interruption) and disconnection hyperprolactinaemia (loss of dopamine inhibition; prolactin usually < 100–150 ng/mL — distinguish from prolactinoma).
Order of pituitary hormone loss: GH → FSH/LH → TSH → ACTH.
Hypothalamic morbidity (obesity, temperature dysregulation, sleep/behavioural disturbance) is the most devastating long-term consequence.
Diencephalic syndrome in infants: paradoxical emaciation from anterior hypothalamic dysfunction.
Raised ICP signs: headache (worse in morning), vomiting, papilloedema, ↓consciousness, Cushing's triad (late).

High Yield Summary — DDx of Craniopharyngioma

The differential is that of a sellar/suprasellar mass.
In children: craniopharyngioma (most common suprasellar tumour), optic pathway glioma (NF1), germinoma, LCH.
In adults: pituitary adenoma (most common), meningioma, craniopharyngioma (2nd peak), metastasis, Rathke's cleft cyst, lymphocytic hypophysitis.
Key distinguishing features of craniopharyngioma: calcification (50–90%) + cystic + childhood + hormonally inert (only deficiency, never secretion).
DI at presentation favours craniopharyngioma, germinoma, LCH, metastasis, or hypophysitis — NOT pituitary adenoma.
Disconnection hyperprolactinaemia (PRL < 100–150): distinguishes stalk compression from a true prolactinoma (PRL typically > 200 in macroadenoma).
CT is better for calcified tumours (meningioma, craniopharyngioma); MRI is the modality of choice for anatomical delineation.
Always exclude vascular lesion (carotid aneurysm) before surgical intervention on any sellar mass.

High Yield Summary — Investigations for Craniopharyngioma

CT: best for detecting calcification (the hallmark — present in 50–90% of adamantinomatous type). CT is better for calcified tumours (meningioma, craniopharyngioma) ^[6].
MRI with contrast: modality of choice for anatomical delineation; look for T1-hyperintense cyst (cholesterol), enhancing solid components, relationship to chiasm/hypothalamus/stalk, loss of posterior pituitary bright spot (DI) ^[11].
Endocrine workup: assess ALL pituitary axes (GH/IGF-1, FSH/LH/sex steroids, ACTH/cortisol, TSH/fT4, prolactin, serum/urine osmolality). Dynamic tests (ITT, SST) for equivocal cases.
Water deprivation test ± copeptin: confirm and classify DI (central vs nephrogenic). Copeptin is a safer, newer alternative ^[12].
Formal visual field testing: bitemporal hemianopia is one of the four classical presentations ^[2].
Tumour markers (AFP, β-hCG): serum AND CSF — mandatory in paediatric suprasellar masses to exclude germ cell tumours ^[8]^[9].
Histopathology: gold standard; CTNNB1 (adamantinomatous) vs BRAF V600E (papillary).
Prolactin level helps distinguish stalk-effect ( < 100–150) from prolactinoma ( > 200 or > 10× ULN) ^[2].

High Yield Summary — Management of Craniopharyngioma

Surgery is the primary treatment — the approach is transsphenoidal (route of choice) for sellar/infrasellar tumours; transcranial for very large suprasellar extension or severe chiasmal compression ^[2].
Maximum safe resection — the goal is to remove as much tumour as safely possible while preserving hypothalamic and optic function. The concept of resection margin does not apply in neurosurgery ^[14].
GTR vs STR + RT: modern approach favours hypothalamus-sparing STR + adjuvant RT if tumour is adherent to hypothalamus. Hypothalamic morbidity from aggressive surgery is often worse than the tumour itself.
Pre-op cortisol replacement is mandatory — start hydrocortisone BEFORE thyroxine (risk of Addisonian crisis) ^[4].
Post-op monitoring: watch for triphasic DI response (DI → SIADH → DI) — monitor I/O, Na, urine osmolality daily ^[4].
CSF rhinorrhoea: test for β2-transferrin; requires antibiotics and possible surgical repair ^[2].
Lifelong hormone replacement: hydrocortisone, levothyroxine (monitor fT4 not TSH), sex steroids ± gonadotropins, GH, DDAVP ^[4].
BRAF + MEK inhibitors (dabrafenib + trametinib): transformative for BRAF V600E-mutant papillary craniopharyngioma — dramatic tumour shrinkage reported.
Radiotherapy: fractionated EBRT, proton beam (children), or stereotactic radiosurgery for residual/recurrent disease.
Surveillance is lifelong — MRI, hormones, visual fields, growth (children), neurocognitive assessment.

High Yield Summary — Complications of Craniopharyngioma

Hypothalamic obesity is the single most devastating complication — caused by surgical damage to the ventromedial hypothalamus (satiety centre); intractable, irreversible, and the strongest argument for hypothalamus-sparing surgery (STR + RT).
Diabetes insipidus is the most common post-operative endocrine complication; watch for the triphasic response (DI → SIADH → DI) — monitor I/O, Na, urine osmolality daily ^[4].
Post-operative hyponatraemia is very common (~30%); causes include SIADH, cerebral salt wasting, or DDAVP over-dosing. Too-rapid correction of chronic hyponatraemia causes central pontine myelinolysis ("patients become tetraplegic") ^[16].
CSF rhinorrhoea: diagnose with β2-transferrin; treat with antibiotics + surgical repair to prevent ascending meningitis ^[2]^[4].
Radiotherapy complications: GH lost first (94%), ACTH (43%), TSH (10%); also optic neuropathy, neurocognitive decline, cerebrovascular disease (Moyamoya), and secondary malignancy ^[8]^[9].
Shunt complications: blockage (most common — 80% proximal), infection (S. epidermidis, S. aureus — most serious), overshunting (→ SDH) ^[15].
Long-term: growth failure, infertility, osteoporosis, cardiovascular morbidity, psychosocial dysfunction — all require lifelong MDT follow-up.
Prevention is key: hypothalamus-sparing surgery, adequate perioperative steroid cover, proton beam RT in children to minimise late effects.

Craniopharyngioma

1. Definition

2. Epidemiology

3. Anatomy and Functional Relationships

3.1 Rathke's Pouch — The Embryological Origin

3.2 Critical Neighbouring Structures

3.3 The Pituitary Stalk — Why Stalk Compression Causes DI and Hyperprolactinaemia

4. Aetiology and Pathophysiology

4.1 Aetiology

4.2 Pathology

Adamantinomatous Craniopharyngioma (ACP)

Papillary Craniopharyngioma (PCP)

4.3 Pathophysiology of Clinical Effects

5. Classification

5.1 WHO Classification (2021 CNS Tumours, 5th Edition)

5.2 Anatomical/Topographical Classification

5.3 Comparison Table: Adamantinomatous vs Papillary

6. Clinical Features

Overview of Presentation

6.1 Symptoms (with Pathophysiological Basis)

A. Visual Symptoms

B. Endocrine Symptoms

C. Raised Intracranial Pressure Symptoms

D. Hypothalamic Symptoms

E. Other Symptoms

6.2 Signs (with Pathophysiological Basis)

A. Ophthalmological Signs

B. Endocrine Signs

C. Neurological Signs

D. General / Constitutional Signs

7. Clinical Approach — Pattern Recognition

In a Child

In an Adult

8. Summary Table: Craniopharyngioma at a Glance

Active Recall - Craniopharyngioma (Definition to Clinical Features)

References

Approach to the Differential

Master Differential Diagnosis Table

A. Neoplastic — Benign

B. Neoplastic — Malignant / Aggressive

C. Cystic Lesions (Non-neoplastic)

D. Inflammatory / Infectious / Other

E. Vascular

Differential by Age Group

Optic Pathway Glioma — A Special Paediatric Differential

Key Distinguishing Investigations

The "Stalk Thickening" Differential

Differential by Presenting Feature

If the Patient Presents with Bitemporal Hemianopia

If the Patient Presents with Diabetes Insipidus

If the Patient Presents with Growth Failure in Childhood

Differential Summary Mermaid Diagram — By Pathological Category

Why Each Differential Matters — Key "Why" Explanations

Active Recall - Craniopharyngioma Differential Diagnosis

1. Diagnostic Criteria — A Practical Framework

2. Diagnostic Algorithm

3. Investigation Modalities — Detailed Breakdown

3.1 Neuroimaging

A. CT Brain (without and with contrast)

B. MRI Pituitary / Brain (with Gadolinium contrast)

C. Skull X-ray (SXR)

D. CT/MR Angiography (CTA/MRA)

3.2 Endocrine Investigations

A. Baseline Hormonal Profile (Screening)

B. Dynamic (Stimulation) Tests

C. Water Deprivation Test (WDT) and Copeptin

3.3 Visual Assessment

3.4 Tumour Markers (to Exclude Germ Cell Tumours)

3.5 Additional Investigations

4. Interpretation Framework — Putting It All Together

5. Summary of Diagnostic Approach

Active Recall - Craniopharyngioma Diagnosis and Investigations

1. Overview of Management Philosophy

2. Management Algorithm

3. Pre-operative Management

3.1 Hormone Assessment and Replacement BEFORE Surgery

3.2 Emergency Management of Hydrocephalus

3.3 Glucocorticoid Cover Perioperatively

4. Surgical Treatment

4.1 Surgical Approaches